<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006022.pub3" GROUP_ID="RENAL" ID="012805041413484775" MERGED_FROM="" MODIFIED="2014-02-05 21:16:09 +0000" MODIFIED_BY="Narelle Willis" REVIEW_NO="081" REVMAN_SUB_VERSION="5.2.7 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2014-02-05 21:16:09 +0000" MODIFIED_BY="Narelle Willis">
<TITLE>Dietary interventions for preventing complications in idiopathic hypercalciuria</TITLE>
<CONTACT MODIFIED="2014-02-05 21:16:09 +0000" MODIFIED_BY="Narelle Willis"><PERSON ID="15209" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Joaquin</FIRST_NAME><LAST_NAME>Escribano</LAST_NAME><POSITION>Titular Professor</POSITION><EMAIL_1>JESCRIBANO@GRUPSAGESSA.COM</EMAIL_1><ADDRESS><DEPARTMENT>Department of Pediatrics</DEPARTMENT><ORGANISATION>Hospital Universitari St Joan de Reus</ORGANISATION><ADDRESS_1>Universitat Rovira i Virgili</ADDRESS_1><ADDRESS_2>St Joan s/n</ADDRESS_2><CITY>Reus</CITY><ZIP>43201</ZIP><REGION>Catalonia</REGION><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+34 977 310300 ext: 313</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2014-02-05 21:16:09 +0000" MODIFIED_BY="Narelle Willis"><PERSON ID="15209" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Joaquin</FIRST_NAME><LAST_NAME>Escribano</LAST_NAME><POSITION>Titular Professor</POSITION><EMAIL_1>JESCRIBANO@GRUPSAGESSA.COM</EMAIL_1><ADDRESS><DEPARTMENT>Department of Pediatrics</DEPARTMENT><ORGANISATION>Hospital Universitari St Joan de Reus</ORGANISATION><ADDRESS_1>Universitat Rovira i Virgili</ADDRESS_1><ADDRESS_2>St Joan s/n</ADDRESS_2><CITY>Reus</CITY><ZIP>43201</ZIP><REGION>Catalonia</REGION><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+34 977 310300 ext: 313</PHONE_1></ADDRESS></PERSON><PERSON ID="3FC185BD82E26AA2010EE5B849927713" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Albert</FIRST_NAME><LAST_NAME>Balaguer</LAST_NAME><POSITION>Director</POSITION><EMAIL_1>abalaguer@uic.es</EMAIL_1><EMAIL_2>balaguer.albert@gmail.com</EMAIL_2><ADDRESS><DEPARTMENT>Department of Pediatrics. Hospital General de Catalunya.</DEPARTMENT><ORGANISATION>Universitat Internacional de Catalunya</ORGANISATION><ADDRESS_1>C/ Pedro I Pons, 1</ADDRESS_1><ADDRESS_2>Sant Cugat de Vallés</ADDRESS_2><CITY>Barcelona</CITY><ZIP>08195</ZIP><REGION>CATALONIA</REGION><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+34 935042000</PHONE_1><FAX_1>+34 935042001</FAX_1></ADDRESS></PERSON><PERSON ID="AAD7845D82E26AA20130726F85E76FD4" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Marta</FIRST_NAME><LAST_NAME>Roqué i Figuls</LAST_NAME><POSITION>Statistician</POSITION><EMAIL_1>mroque@santpau.es</EMAIL_1><ADDRESS><DEPARTMENT>Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau)</DEPARTMENT><ORGANISATION>CIBER Epidemiología y Salud Pública (CIBERESP)</ORGANISATION><ADDRESS_1>Sant Antoni Maria Claret 171</ADDRESS_1><ADDRESS_2>Edifici Casa de Convalescència</ADDRESS_2><CITY>Barcelona</CITY><ZIP>08041</ZIP><REGION>Catalunya</REGION><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+34 935 537 814</PHONE_1><PHONE_2>+34 935 537 808</PHONE_2><FAX_1>+34 935 537 809</FAX_1></ADDRESS></PERSON><PERSON ID="3FC4C88482E26AA2010EE5B867BA63FD" ROLE="AUTHOR"><PREFIX>A/Prof</PREFIX><FIRST_NAME>Albert</FIRST_NAME><LAST_NAME>Feliu</LAST_NAME><POSITION>Pediatrician</POSITION><EMAIL_1>afeliu@grupsagessa.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Pediatrics</DEPARTMENT><ORGANISATION>Hospital Universitari St Joan de Reus</ORGANISATION><ADDRESS_1>Universitat Rovir i Virgili</ADDRESS_1><ADDRESS_2>St Joan s/n</ADDRESS_2><CITY>Reus</CITY><ZIP>43201</ZIP><REGION>Catalonia</REGION><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+34 977 310300 ext 325</PHONE_1></ADDRESS></PERSON><PERSON ID="69479809656470482060120717014549" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Natalia</FIRST_NAME><LAST_NAME>Ferre</LAST_NAME><EMAIL_1>natalia.ferre@urv.cat</EMAIL_1><ADDRESS><DEPARTMENT>Pediatric Research Unit, School of Medicine</DEPARTMENT><ORGANISATION>Universitat Rovira i Virgili</ORGANISATION><ADDRESS_1>Sant Lloreç, 21</ADDRESS_1><CITY>Tarragona</CITY><ZIP>43201</ZIP><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+34 977759305</PHONE_1><FAX_1>+34 977759322</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2014-01-29 10:04:33 +1100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="23" MONTH="4" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="23" MONTH="4" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="23" MONTH="10" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2008"/>
</DATES>
<WHATS_NEW MODIFIED="2011-07-20 17:03:51 +1000" MODIFIED_BY="Narelle S Willis"/>
<HISTORY MODIFIED="2008-07-21 11:27:15 +1000" MODIFIED_BY="Narelle S Willis"/>
<SOURCES_OF_SUPPORT MODIFIED="2014-02-04 14:32:53 +1100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2014-02-04 14:32:53 +1100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2014-01-02 05:28:07 +1100" MODIFIED_BY="[Empty name]">
<NAME>Department of Pediatrics. Hospital Universitari Sant Joan de Reus</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2014-01-02 05:19:09 +1100" MODIFIED_BY="[Empty name]">
<NAME>Universitat Rovira i Virgili</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2014-01-02 05:23:06 +1100" MODIFIED_BY="[Empty name]">
<NAME>Unitat de Recerca en Pediatria, Nutrició i Desenvolupament Humà. IISPV</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2014-02-04 14:32:44 +1100" MODIFIED_BY="[Empty name]">
<NAME>Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2014-02-04 14:32:53 +1100" MODIFIED_BY="[Empty name]">
<NAME>Department of Pediatrics. Hospital General de Catalunya, Universitat Internacional de Catalunya</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2014-01-02 05:30:06 +1100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2014-01-02 05:30:06 +1100" MODIFIED_BY="[Empty name]">
<NAME>Instituto de Salud Carlos III. Subdirección General de Investigación Sanitaria, (01/A060)</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-02-06 08:08:54 +1100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2014-02-04 15:57:54 +1100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2014-02-04 15:57:54 +1100" MODIFIED_BY="Narelle S Willis">Dietary interventions for preventing complications in idiopathic hypercalciuria</TITLE>
<SUMMARY_BODY MODIFIED="2014-02-04 15:43:08 +1100" MODIFIED_BY="[Empty name]">
<P>Hypercalciuria, an inherited metabolic condition, is the presence of excessive calcium in the urine. The cause is often unknown (idiopathic), and may occur in people who are otherwise well. Although people with the condition have normal levels of calcium in their blood, calcium is lost through the urine.</P>
<P>Adults with hypercalciuria are prone to developing kidney stones and losing calcium from their bones. In children, hypercalciuria can cause blood in the urine (haematuria), frequency-dysuria syndrome (frequent painful or difficult urination), urinary tract infections, abdominal and back pain.</P>
<P>It has been suggested that altering the diets of people with hypercalciuria could help to prevent complications of the condition. We therefore aimed to evaluate the benefits and harms of dietary interventions that had been investigated in clinical studies. We included five studies in our review, one of which compared a low calcium diet with a diet that included normal levels of calcium, low protein, low salt over five years. This study found that diets unrestricted for calcium intake significantly decreased numbers of new kidney stones.</P>
<P>Other dietary interventions, such as unprocessed wheat bran, did not show any evidence of beneficial effects.</P>
<P>We did not find any studies in children, and none investigating specific dietary recommendations for those who had hypercalciuria without symptoms.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-02-06 08:08:54 +1100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2014-02-04 17:54:19 +1100" MODIFIED_BY="[Empty name]">
<P>Idiopathic hypercalciuria is an inherited metabolic abnormality that is characterised by excessive amounts of calcium excreted in the urine by people whose calcium serum levels are normal. Morbidity associated with idiopathic hypercalciuria is chiefly related to kidney stone disease and bone demineralisation leading to osteopenia and osteoporosis. Idiopathic hypercalciuria contributes to kidney stone disease at all life stages; people with the condition are prone to developing oxalate and calcium phosphate kidney stones. In some cases, crystallised calcium can be deposited in the renal interstitium, causing increased calcium levels in the kidneys. In children, idiopathic hypercalciuria can cause a range of comorbidities including recurrent macroscopic or microscopic haematuria, frequency dysuria syndrome, urinary tract infections and abdominal and lumbar pain. Various dietary interventions have been described that aim to decrease urinary calcium levels or urinary crystallisation.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2014-02-04 11:45:00 +1100" MODIFIED_BY="[Empty name]">
<P>Our objectives were to assess the efficacy, effectiveness and safety of dietary interventions for preventing complications in idiopathic hypercalciuria (urolithiasis and osteopenia) in adults and children, and to assess the benefits of dietary interventions in decreasing urological symptomatology in children with idiopathic hypercalciuria.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-02-04 15:44:29 +1100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Renal Group's Specialised Register (23 April 2013) through contact with the Trials' Search Co-ordinator using search terms relevant to this review. Studies contained in the Specialised Register are identified through search strategies specifically designed for CENTRAL, MEDLINE and EMBASE.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2014-02-04 11:56:37 +1100" MODIFIED_BY="[Empty name]">
<P>We included all randomised controlled trials (RCTs) and quasi-RCTs that investigated dietary interventions aimed at preventing complications of idiopathic hypercalciuria, compared with placebo, no intervention, or other dietary interventions regardless of route of administration, dose or amount.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-02-04 11:54:51 +1100" MODIFIED_BY="[Empty name]">
<P>Studies were assessed for inclusion and data extracted using a standardised data extraction form. We calculated risk ratios (RR) for dichotomous outcomes and mean differences (MD) for continuous outcomes, both with 95% confidence intervals (CI).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-02-06 08:08:54 +1100" MODIFIED_BY="[Empty name]">
<P>We included five studies (379 adult participants) that investigated a range of interventions. Lack of similarity among interventions investigated meant that data could not be pooled. Overall, study methodology was not adequately reported in any of the included studies. There was a high risk of bias associated with blinding (although it seems unlikely that outcomes measures were unduly influenced by lack of intervention blinding), random sequence generation and allocation methodologies were unclear in most studies, but selective reporting bias was assessed as low.</P>
<P>One study (120 participants) compared a low calcium diet with a normal calcium, low protein, low salt diet for five years. There was a significant decrease in numbers of new stone recurrences in those treated with the normal calcium, low protein, low salt diet (RR 0.77, 95% CI 0.61 to 0.98). This diet also led to a significant decrease in oxaluria (MD 78.00 µmol/d, 95% CI 26.48 to 129.52) and the calcium oxalate relative supersaturation index (MD 1.20 95% CI 0.21 to 2.19).</P>
<P>One study (210 participants) compared a low salt, normal calcium diet with a broad diet for three months. The low salt, normal calcium diet decreased urinary calcium (MD -45.00 mg/d, 95% CI -74.83 to -15.17) and oxalate excretion (MD -4.00 mg/d, 95% CI -6.44 to -1.56).</P>
<P>A small study (17 participants) compared the effect of dietary fibre as part of a low calcium, low oxalate diet over three weeks, and found that although calciuria levels decreased, oxaluria increased.</P>
<P>
<I>Phyllanthus niruri </I>plant substrate intake was investigated in a small subgroup with hypercalciuria (20 participants); there was no significant effect on calciuria levels occurred after three months of treatment.</P>
<P>A small cross-over study (12 participants) evaluating the changes in urinary supersaturation indices among patients who consumed calcium-fortified orange juice or milk for one month found no benefits for participants.</P>
<P>None of the studies reported any significant adverse effects associated with the interventions.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-02-04 18:56:30 +1100" MODIFIED_BY="[Empty name]">
<P>Long-term adherence (five years) to diets that feature normal levels of calcium, low protein and low salt may reduce numbers of stone recurrences, decrease oxaluria and calcium oxalate relative supersaturation indexes in people with idiopathic hypercalciuria who experience recurrent kidney stones. Adherence to a low salt, normal calcium level diet for some months can reduce calciuria and oxaluria. However, the other dietary interventions examined did not demonstrate evidence of significant beneficial effects.</P>
<P>No studies were found investigating the effect of dietary recommendations on other clinical complications or asymptomatic idiopathic hypercalciuria.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-02-06 08:08:54 +1100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2014-02-06 08:08:54 +1100" MODIFIED_BY="[Empty name]">
<P>Idiopathic hypercalciuria is a relatively common hereditary metabolic anomaly. Reported prevalence rates in the healthy population vary between 2.9% and 6.5% (<LINK REF="REF-Caballero-2000" TYPE="REFERENCE">Caballero 2000</LINK>).</P>
<P>Idiopathic hypercalciuria is defined as daily urinary calcium excretion of &gt; 250 mg for women, and 275 to 300 mg for men, whose diet is unrestricted, and in the absence of secondary causes such as primary hyperparathyroidism, renal tubular acidosis, malignancy, vitamin D intoxication, immobilisation, hyperthyroidism, or Bartter's syndrome (<LINK REF="REF-Langman-1984" TYPE="REFERENCE">Langman 1984</LINK>). The condition has also been defined as excretion of urinary calcium &gt; 4 mg/kg body weight/d in children (<LINK REF="REF-Ghazali-1974" TYPE="REFERENCE">Ghazali 1974</LINK>).</P>
<P>Although hypercalciuria is thought to be related to osteopenia and osteoporosis, the pathophysiological mechanisms of bone loss are unknown. Dietary issues, genetic factors, hormonal influences, and local cytokines appear to be associated with altered bone formation in people with hypercalciuria (<LINK REF="REF-Asplin-2003" TYPE="REFERENCE">Asplin 2003</LINK>; <LINK REF="REF-Freundlich-2002" TYPE="REFERENCE">Freundlich 2002</LINK>; <LINK REF="REF-Sakhaee-2011" TYPE="REFERENCE">Sakhaee 2011</LINK>). People with hypercalciuria have negative calcium balance - the amount of calcium excreted in urine exceeds the amount consumed; and therefore, all instances of hypercalciuria have bone involvement (<LINK REF="REF-Pak-2003" TYPE="REFERENCE">Pak 2003</LINK>). It has been estimated that 30% to 40% of children and adults with idiopathic hypercalciuria have osteopenia. Osteopenia increases osteoporotic fracture risk in adults, but the long-term impact remains unknown in children (<LINK REF="REF-Garcia_x002d_Nieto-1997" TYPE="REFERENCE">Garcia-Nieto 1997</LINK>; <LINK REF="REF-Sakhaee-2011" TYPE="REFERENCE">Sakhaee 2011</LINK>).</P>
<CONDITION MODIFIED="2014-02-04 18:17:21 +1100" MODIFIED_BY="[Empty name]">
<P>Idiopathic hypercalciuria is complex condition attributed to factors that affect calcium-phosphorus metabolism. Hypercalciuria contributes to kidney stone disease in both adults and children (<LINK REF="REF-Stapleton-1987" TYPE="REFERENCE">Stapleton 1987</LINK>). In industrialised nations, kidney stones occur in 15% of men and 6% of women, and recurrence is approximately 50% (<LINK REF="REF-Bihl-2001" TYPE="REFERENCE">Bihl 2001</LINK>).</P>
<P>Hypercalciuria in people whose calcium levels are normal may be classified as absorptive (types I and II), renal hypercalciuria, and renal phosphate leak (absorptive hypercalciuria type III) types. However, subtypes are not well defined clinically, and patients may have features common to more than one type. Mechanisms include reduced kidney tubule reabsorption and calcium transport. Parathyroid hormone (PTH) is widely accepted to play a significant role in altering urinary calcium levels, but this is unlikely sufficient account for the total effect found among people with hypercalciuria (<LINK REF="REF-Worcester-2007" TYPE="REFERENCE">Worcester 2007</LINK>). Loss of renal phosphate in the presence of normal PTH plasma levels increases calciuria, independent of calcium intake. Hypophosphataemia caused by renal phosphate leakage may contribute to calcium stone formation by increasing serum calcitriol, calcium excretion, and urinary saturation (<LINK REF="REF-Prie-2001" TYPE="REFERENCE">Prie 2001</LINK>; <LINK REF="REF-Williams-1996" TYPE="REFERENCE">Williams 1996</LINK>).</P>
<P>Calcium stones attach to areas of renal papillae that contain interstitial apatite deposits. Deposits of calcium phosphate that originate in the ascending limb of the loop of Henle, known as Randall's plaques, form in response to high levels of calcium in the urine, reduced urine volume, and pH causing loss of urothelial integrity (<LINK REF="REF-Kuo-2003" TYPE="REFERENCE">Kuo 2003</LINK>). Urinary proteins with affinity for apatite form layers covering exposed plaques. When urine supersaturation exceeds the moderating effects of these proteins, aggregated crystals create stones (<LINK REF="REF-Evan-2007" TYPE="REFERENCE">Evan 2007</LINK>). Stone formation is inhibited by magnesium, citrate, and pyrophosphate which prevent crystallisation. About 80% of all kidney stones contain calcium, and at least 40% to 60% of all people who develop calcium stones are found to have hypercalciuria (<LINK REF="REF-Lerolle-2002" TYPE="REFERENCE">Lerolle 2002</LINK>).</P>
<P>In children, hypercalciuria can cause a wide range of symptoms: the most common is recurrent macroscopic or microscopic haematuria. Other common manifestations in children are frequency-dysuria syndrome, abdominal and lumbar pain. Recurrent urinary infection is also common (<LINK REF="REF-Vachvanichsanong-2001" TYPE="REFERENCE">Vachvanichsanong 2001</LINK>).</P>
<P>Urinary tract stone-related morbidity is primarily related to obstruction and pain, although non-obstructing stones can be responsible for considerable discomfort. Obstructing stones can be asymptomatic, which is a factor in the outcomes of the relatively small number of people who experience kidney loss from chronic, untreated obstruction. Although kidney stones are not a significant cause of kidney failure, epidemiological data suggest that most people who develop kidney stones have mildly compromised kidney function (<LINK REF="REF-Gillen-2005" TYPE="REFERENCE">Gillen 2005</LINK>). The most potentially dangerous aspect of stone disease is the combination of obstruction and infection of the upper urinary tract, which can result in pyelonephritis, pyonephrosis (gross pus in the renal collecting system) and urosepsis (<LINK REF="REF-Leslie-2000" TYPE="REFERENCE">Leslie 2000</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2014-02-06 08:08:54 +1100" MODIFIED_BY="[Empty name]">
<P>Dietary interventions - often involving increased fluid intake - may be suggested for people with idiopathic hypercalciuria, particularly for those who have histories of stone disease with the aim of decreasing urinary calcium supersaturation (<LINK REF="REF-Rodgers-2002" TYPE="REFERENCE">Rodgers 2002</LINK>). Although an observational study reported benefits from increasing fluid intake (<LINK REF="REF-Curhan-1998" TYPE="REFERENCE">Curhan 1998</LINK>), a later study indicated that although increased fluids reduced urinary stone recurrence, it was not beneficial for primary prevention (<LINK REF="REF-Qiang-2004" TYPE="REFERENCE">Qiang 2004</LINK>).</P>
<P>There is lack of consensus about reducing dietary calcium intake: there are indications that this may prevent oxalate absorption in the digestive tract. Although benefits have been reported relating to moderate calcium intake (600 to 800 mg/d) to reduce oxaluria and minimise osteopenia risk, evidence also suggests that excessive dietary calcium (&gt; 2000 mg/d) could counteract any protective effects on oxalate absorption and promote hypercalcaemia, hypercalciuria and stone formation (<LINK REF="REF-Bataille-1983" TYPE="REFERENCE">Bataille 1983</LINK>; <LINK REF="REF-Coe-1982" TYPE="REFERENCE">Coe 1982</LINK>; <LINK REF="REF-Curhan-1997b" TYPE="REFERENCE">Curhan 1997b</LINK>; <LINK REF="REF-Fuss-1990" TYPE="REFERENCE">Fuss 1990</LINK>; <LINK REF="REF-Harward-1993" TYPE="REFERENCE">Harward 1993</LINK>; <LINK REF="REF-Lemann-1996" TYPE="REFERENCE">Lemann 1996</LINK>).</P>
<P>Diets high in animal protein may impose negative effects on people with hypercalciuria by inducing acid overload, inhibiting renal reabsorption of calcium, and increasing urinary excretion. Excess acid may be neutralised, at least partly, by releasing skeletal calcium phosphate into the bloodstream, contributing to increased hypercalciuria. Further problems arise from metabolising animal proteins to purines. Purines are precursors of uric acid, which when plasma levels rise, facilitate formation of uric acid stones. Purines also contribute to excretion of urinary calcium (<LINK REF="REF-Moe-2006" TYPE="REFERENCE">Moe 2006</LINK>).</P>
<P>High protein intake has been associated with increased risk of stone formation (<LINK REF="REF-Curhan-1993" TYPE="REFERENCE">Curhan 1993</LINK>); other studies comparing increased water intake and reduced protein diet have found a very small protective effect (<LINK REF="REF-Breslau-1988" TYPE="REFERENCE">Breslau 1988</LINK>; <LINK REF="REF-Curhan-1993" TYPE="REFERENCE">Curhan 1993</LINK>; <LINK REF="REF-Curhan-1997a" TYPE="REFERENCE">Curhan 1997a</LINK>; <LINK REF="STD-Hiatt-1996" TYPE="STUDY">Hiatt 1996</LINK>; <LINK REF="REF-Liatsikos-1999" TYPE="REFERENCE">Liatsikos 1999</LINK>). <LINK REF="REF-Siener-2005" TYPE="REFERENCE">Siener 2005</LINK> identified low fluid intake and increased protein and alcohol intake as significant dietary risk factors.</P>
<P>It has been suggested that restricting dietary oxalate could be a protective factor (<LINK REF="REF-Assimos-2000" TYPE="REFERENCE">Assimos 2000</LINK>). People with high intakes of ascorbic acid excreted high levels of oxalate, but were not found to be more likely to develop stones (<LINK REF="REF-Curhan-1999" TYPE="REFERENCE">Curhan 1999</LINK>).</P>
<P>High levels of dietary sodium intake have also been linked to risk of developing hypercalciuria and stones. Bone calcium release increases when salt intake is high, and the direct effect of sodium on the kidney is increased calcium excretion (<LINK REF="REF-Bourdeau-1994" TYPE="REFERENCE">Bourdeau 1994</LINK>
<U>; </U>
<LINK REF="REF-Frassetto-2007" TYPE="REFERENCE">Frassetto 2007</LINK>
<U>)</U>. Salt restriction has been correlated with decreased calciuria levels in people with hypercalciuria (<LINK REF="REF-Breslau-1982" TYPE="REFERENCE">Breslau 1982</LINK>; <LINK REF="REF-Martini-2000" TYPE="REFERENCE">Martini 2000</LINK>; <LINK REF="REF-Muldowney-1982" TYPE="REFERENCE">Muldowney 1982</LINK>; <LINK REF="REF-Sakhaee-1993" TYPE="REFERENCE">Sakhaee 1993</LINK>). Evidence suggest that diets to reduce calcium and oxalate excretion by restricting intake of dietary calcium, oxalate, sodium, and meat products were beneficial in reducing urinary calcium oxalate saturation in people with hypercalciuria (<LINK REF="REF-Pak-2005" TYPE="REFERENCE">Pak 2005</LINK>).</P>
<P>A relatively low intake of potassium may promote stone formation in susceptible people (<LINK REF="REF-Curhan-1993" TYPE="REFERENCE">Curhan 1993</LINK>; <LINK REF="REF-Heilberg-2000" TYPE="REFERENCE">Heilberg 2000</LINK>).</P>
<P>Consumption of alcohol and coffee can affect onset of pathologies secondary to hypercalciuria. Ethanol from alcoholic drinks may decrease osteoblastic activity and PTH levels, increasing urinary excretion of calcium, leading to osteoporosis (<LINK REF="REF-de-Vernejoul-1983" TYPE="REFERENCE">de Vernejoul 1983</LINK>; <LINK REF="REF-Garcia_x002d_Sanchez-1995" TYPE="REFERENCE">Garcia-Sanchez 1995</LINK>). Excessive coffee drinking has been reported to increase calcium excretion (<LINK REF="REF-Morgan-1994" TYPE="REFERENCE">Morgan 1994</LINK>). Among people who are susceptible to stone formation, restricting intake of soft drinks containing phosphoric acid could decrease incidence of stone formation (<LINK REF="REF-Shuster-1992" TYPE="REFERENCE">Shuster 1992</LINK>).</P>
<P>Some plant infusions are thought to decrease stone recurrence in people who are not hypercalciuric (<LINK REF="REF-Premgamone-2001" TYPE="REFERENCE">Premgamone 2001</LINK>). Similarly, some fruit juices - such as cranberry juice - may be protective (<LINK REF="REF-McHarg-2003" TYPE="REFERENCE">McHarg 2003</LINK>). However, for reasons that have not been fully explained, grapefruit juice was associated with increased risk of stone formation in two cohort studies conducted in a population who were not hypercalciuric (<LINK REF="REF-Curhan-1996" TYPE="REFERENCE">Curhan 1996</LINK>; <LINK REF="REF-Curhan-1998" TYPE="REFERENCE">Curhan 1998</LINK>).</P>
<P>Other dietary interventions include limiting refined carbohydrates, which may favour intestinal calcium absorption, and fibre consumption, which bonds to the free calcium in the intestinal lumen and may decrease its absorption (<LINK REF="REF-Ebisuno-1986" TYPE="REFERENCE">Ebisuno 1986</LINK>; <LINK REF="REF-Jahnen-1992" TYPE="REFERENCE">Jahnen 1992</LINK>).</P>
<P>
<I>Phyllanthus niruri, </I>a plant traditionally used in Brazil to treat urinary stones, was investigated (<LINK REF="STD-Nishiura-2004" TYPE="STUDY">Nishiura 2004</LINK>). Analysis of a subset of patients exhibiting hypercalciuria found that <I>P. niruri</I> reduced urinary calcium, but did not reduce stone voiding or provide pain relief.</P>
<P>Most studies analysing the effectiveness of dietary interventions for prevention of kidney stones address that the disease course is slow and variable. The average rate of stone formation in people who develop recurrent stones is approximately 0.15 to 0.20 stones/y (<LINK REF="REF-Tiselius-2000" TYPE="REFERENCE">Tiselius 2000</LINK>). Thus, studies that attempt to demonstrate the efficacy of specific treatment programs must last for several years.</P>
</INTERVENTION>
<IMPORTANCE MODIFIED="2014-02-04 18:56:33 +1100" MODIFIED_BY="[Empty name]">
<P>We analysed the various dietary strategies for controlling the disease clinically to see if it was possible to control the disease metabolically and to decrease the levels of excretion of urinary calcium, and to reduce the main clinical manifestations.</P>
<P>For the dietary management of hypercalciuria it is necessary to consider two basic factors which are particularly important in the formation of kidney stones and bone health.</P>
<UL>
<LI>It should be established dietary strategies aimed to reduce calcium or oxalate excretion, intended to achieve lower calcium oxalate complex formation. These diets may promote the prolonged reduction of one or both metabolites mentioned to reduce the incidence of new kidney stones</LI>
<LI>Simultaneously it is necessary to design dietary strategies that do not generate a negative calcium balance that may cause bone-loss.</LI>
</UL>
<P>To achieve these two objectives is logical to think that the structure of the diet should be balanced, and will affect more than one component. Therefore the most effective diet is likely to be a multicomponent diet.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-02-06 08:07:46 +1100" MODIFIED_BY="Narelle S Willis">
<P>Our objectives were to assess:</P>
<UL>
<LI>the efficacy, effectiveness and safety of dietary interventions for preventing complications in idiopathic hypercalciuria (urolithiasis and osteopenia) in adults and children; and</LI>
<LI>the benefits of dietary interventions in decreasing urological symptomatology in children with idiopathic hypercalciuria.</LI>
</UL>
</OBJECTIVES>
<METHODS MODIFIED="2014-02-04 18:38:02 +1100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2014-02-04 18:30:04 +1100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2013-03-21 14:38:18 +1100" MODIFIED_BY="[Empty name]">
<P>All randomised controlled trials (RCTs) and quasi-RCTs (RCTs in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods) looking at the benefits and harms of<B> </B>dietary interventions for preventing complications in people with idiopathic hypercalciuria.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2014-02-04 18:26:07 +1100" MODIFIED_BY="Narelle S Willis">
<SUBSECTION>
<HEADING LEVEL="4">Inclusion criteria</HEADING>
<P>We included people (men and women, adults and children) with hypercalciuria, regardless of stone formation status, among whom dietary interventions were introduced with the aim of decreasing risk or recurrence of stones, and to eliminate symptoms such as dysuria, haematuria, and abdominal pain. Hypercalciuria was defined as daily urinary excretion of more than 300 mg Ca/d (7.5 mmol) in adult men and &gt; 250 mg Ca/d (6.25 mmol) in adult women who were on regular unrestricted diets; or excretion of urinary calcium of &gt; 4 mg/kg body weight/d in children and adults.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Exclusion criteria</HEADING>
<P>We excluded participants with secondary hypercalciuria, such as primary hyperparathyroidism, renal tubular acidosis, malignancy, vitamin D intoxication, immobilisation, hyperthyroidism, Bartter's syndrome, sarcoidosis, sponge kidney, or conditions associated with causing osteopenia or urolithiasis, such as primary hyperoxaluria, enteric hyperoxaluria, bowel resection, or inflammatory bowel disease. We further excluded those who were chronic users of drugs with capacity to increase risks of calcium stone formation, such as vitamin D, acetazolamide, and antiepileptic drugs.</P>
</SUBSECTION>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-03-27 12:20:53 +1100" MODIFIED_BY="[Empty name]">
<P>Studies investigating any dietary intervention aimed to prevent complications in people with idiopathic hypercalciuria compared with placebo, no interventions, other dietary intervention or a different administration mode or amount of the same treatment were eligible for inclusion. We assessed only studies with minimum durations of one year to evaluate effects on kidney stone recurrence and other urological symptoms, and a minimum of two weeks to assess effects of calcium or oxalate urinary excretion rates.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-02-04 18:30:04 +1100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2014-02-04 18:30:04 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Reduction in stone formation: stone rate or calcium stone recurrence, or increases in numbers of stone-free patients. Stone rate was defined as the number of stones per patient per year over a minimum duration of one year. New stone occurrence was defined by radiography, ultrasonography, pyelography or helical CT scan. All patients were stone-free before therapy</LI>
<LI>Reduction in episodes of renal colic</LI>
<LI>Increase or no reduction in bone mass: dual-energy X-ray, absorptiometry over a minimum duration of one year</LI>
<LI>Reduction in urinary symptoms: incidence of urinary tract infection (UTI), haematuria, dysuria, or enuresis in children over a minimum duration of six months</LI>
<LI>Improvement in quality of life in terms of days in hospital, days off work or school.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-03-21 15:14:27 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Reduction in calciuria: decrease in 24 hour calciuria or urinary calcium/creatinine ratio</LI>
<LI>Reduction in oxaluria: decrease in 24 hour oxaluria or calcium oxalate relative supersaturation index</LI>
<LI>Reduction in creatinine clearance</LI>
<LI>Adverse events such as:</LI>
<UL>
<LI>gastrointestinal side effects</LI>
<LI>changes in blood pressure</LI>
<LI>fluid/electrolyte imbalances: hyponatraemia, hypercalcaemia, hyperuricaemia, hypokalaemia, hypermagnesaemia, hyperchloraemia, acidosis, hyperglycaemia, hypocitraturia.</LI>
</UL>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-02-04 18:33:17 +1100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2014-02-04 18:32:57 +1100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Renal Group's Specialised Register (23 April 2013) through contact with the Trials' Search Co-ordinator using search terms relevant to this review. The Cochrane Renal Group&#8217;s Specialised Register contains studies identified from:</P>
<UL>
<LI>Monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL)</LI>
<LI>Weekly searches of MEDLINE OVID SP</LI>
<LI>Handsearching of renal-related journals and the proceedings of major renal conferences</LI>
<LI>Searching the current year of EMBASE OVID SP</LI>
<LI>Weekly current awareness alerts for selected renal journals</LI>
<LI>Searches of the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.</LI>
</UL>
<P>Studies contained in the Specialised Register are identified through search strategies for CENTRAL, MEDLINE, and EMBASE based on the scope of the Cochrane Renal Group. Details of these strategies, as well as a list of handsearched journals, conference proceedings and current awareness alerts, are available in the Specialised Register section of information about the <A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/RENAL/frame.html">Cochrane Renal Group</A>.</P>
<P>See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for search terms used in strategies for this review.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2014-02-04 18:33:17 +1100" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>Reference lists of nephrology textbooks, review articles and relevant studies.</LI>
<LI>Letters seeking information about unpublished or incomplete studies to investigators known to be involved in previous studies.</LI>
</OL>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-02-04 18:38:02 +1100" MODIFIED_BY="Narelle S Willis">
<STUDY_SELECTION MODIFIED="2013-03-27 12:24:33 +1100" MODIFIED_BY="[Empty name]">
<P>The search strategy described was used to obtain titles and abstracts of studies relevant to the review. Titles and abstracts were screened independently by all authors. All authors independently assess retrieved abstracts, and if necessary the full text of these studies, to determine which studies satisfy the inclusion criteria.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2014-02-04 18:34:53 +1100" MODIFIED_BY="Narelle S Willis">
<P>Data were extracted independently by at least three authors using standard data extraction forms. Studies reported in languages other than English or Spanish were translated before assessment. Where more than one publication of one study existed, reports were grouped together and the publication with the most complete data was included. Where relevant outcomes were only published in earlier versions, these data were used. Any discrepancies between published versions were to be highlighted. Any further information required from the original author was requested by written correspondence, and any relevant information obtained in this manner was included in the review. Disagreements were resolved in consultation with another member of the author team.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2014-02-04 15:07:43 +1100" MODIFIED_BY="Narelle S Willis">
<P>The following items were assessed independently by two authors using the risk of bias assessment tool (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) (<I>see</I> <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>).</P>
<UL>
<LI>Was there adequate sequence generation (selection bias)?</LI>
<LI>Was allocation adequately concealed (selection bias)?</LI>
<LI>Was knowledge of the allocated interventions adequately prevented during the study (detection bias)?</LI>
<UL>
<LI>Participants and personnel</LI>
<LI>Outcome assessors</LI>
</UL>
<LI>Were incomplete outcome data adequately addressed (attrition bias)?</LI>
<LI>Are reports of the study free of suggestion of selective outcome reporting (reporting bias)?</LI>
<LI>Was the study apparently free of other problems that could put it at a risk of bias?</LI>
</UL>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2014-02-04 18:30:08 +1100" MODIFIED_BY="Narelle S Willis">
<P>For dichotomous outcomes (new stones, osteopenia, haematuria, frequency-dysuria syndrome, UTI, gastrointestinal side effects) results were expressed as risk ratio (RR) with 95% confidence intervals (CI). Where continuous scales of measurement were used to assess the effects of treatment (decrease in 24 hour calciuria or urinary calcium/creatinine ratio, blood pressure, serum creatinine, natraemia, calcaemia, uricaemia, kalaemia, magnesaemia, chloraemia, acidosis, glycaemia, oxaluria and citraturia), the mean difference (MD) was used, or the standardised mean difference (SMD) where different scales were used.</P>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2013-03-27 12:26:15 +1100" MODIFIED_BY="[Empty name]">
<P>Missing data relevant to this review were sought from authors where necessary. Evaluation of important numerical data such as screened, randomised patients as well as intention-to-treat, as-treated and per-protocol population was carefully performed. Attrition rates, such as drop-outs, losses to follow-up and withdrawals were investigated. Issues of missing data and imputation methods (e.g. last-observation-carried-forward) were critically appraised (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-03-21 16:15:05 +1100" MODIFIED_BY="Narelle S Willis">
<P>Heterogeneity was analysed using a Chi² test on N-1 degrees of freedom, with an alpha of 0.05 used for statistical significance and with the I² test (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). I² values of 25%, 50% and 75% correspond to low, medium and high levels of heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-03-21 15:43:03 +1100" MODIFIED_BY="Narelle S Willis">
<P>We had planned that if sufficient RCTs were identified, examination for reporting bias was to be undertaken using a funnel plot (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). This could not be undertaken because there were insufficient studies identified to enable meaningful funnel plot construction. </P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-03-21 15:44:35 +1100" MODIFIED_BY="[Empty name]">
<P>Data were pooled using the random-effects model, but the fixed effect model was also analysed to ensure robustness of the model chosen and susceptibility to outliers.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2014-02-04 18:38:02 +1100" MODIFIED_BY="Narelle S Willis">
<P>Subgroup analysis was to be undertaken to explore possible sources of heterogeneity (e.g. participants, interventions and study quality). Heterogeneity among participants could be related to stone disease history or age. Heterogeneity in the interventions could be related to dietary intervention duration, or participant compliance to dietary measures. Adverse effects were to be tabulated and assessed using descriptive techniques because they were likely to differ among the interventions investigated. Where possible, risk difference with 95% CI was to be calculated for each adverse effect, either compared with no treatment or another agent.</P>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-02-06 08:08:54 +1100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2014-02-04 18:40:22 +1100" MODIFIED_BY="[Empty name]">
<P>See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
<SEARCH_RESULTS MODIFIED="2014-01-29 10:19:10 +1100" MODIFIED_BY="[Empty name]">
<P>The search strategy described identified 317 references. Titles and abstracts were screened and 171 studies were selected. After further screening 27 records were selected for full text review. After exclusions, five RCTs were included in our analysis. <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> depicts the results of our search strategy.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2014-02-04 18:40:22 +1100" MODIFIED_BY="[Empty name]">
<P>We included five studies that involved a total of 379 adult participants (<LINK REF="STD-Borghi-2002" TYPE="STUDY">Borghi 2002</LINK>; <LINK REF="STD-Gleeson-1990" TYPE="STUDY">Gleeson 1990</LINK>; <LINK REF="STD-Nishiura-2004" TYPE="STUDY">Nishiura 2004</LINK>; <LINK REF="STD-Coe-1992" TYPE="STUDY">Coe 1992</LINK>; <LINK REF="STD-Nouvenne-2010" TYPE="STUDY">Nouvenne 2010</LINK>). With the exception of the cross-over study by <LINK REF="STD-Coe-1992" TYPE="STUDY">Coe 1992</LINK>, all other studies were parallel RCTs that reported on participants with idiopathic hypercalciuria. None of the included studies included children. All outcomes were assessed at the end of the intervention. Studies were classified according to the dietary interventions investigated, but because different interventions were investigated, results could not be pooled for meta-analysis. All studies were published in English.</P>
<UL>
<LI>
<LINK REF="STD-Borghi-2002" TYPE="STUDY">Borghi 2002</LINK> (120 male participants) compared the effects of two diets over five years. One diet aimed to reduce calcium intake (10 mmol/d), and the other reduced protein (&lt; 15% of total energy) and salt (&lt; 50 mmol/d) and included normal-to-high calcium intake (approximately 30 mmol/d). Fluid intake of 2 to 3 L/d of non-mineral water was also recommended for both groups.</LI>
<LI>
<LINK REF="STD-Nouvenne-2010" TYPE="STUDY">Nouvenne 2010</LINK> (210 participants) compared the effect of two diets over three months. Low salt diet (salt &lt; 60 mmol/d) participants (108) were asked to eliminate kitchen salt, strictly limit consumption of high salt content foods and maintain normal calcium intake (800 to 1000 mg/d) by including milk and dairy products. Participants (102) in the control group were asked to maintain their normal dietary habits, and no specific recommendations about calcium or salt intake were provided. Fluid intake of 2 to 3 L/d of a specific mineral water with low sodium and calcium content (Fiuggi water) was also recommended for both groups.</LI>
<LI>
<LINK REF="STD-Gleeson-1990" TYPE="STUDY">Gleeson 1990</LINK> (17 participants) analysed the hypocalciuric effects of unprocessed wheat bran (78 g/d) for three months. Both groups followed diets that limited calcium (300 to 350 mg/d) and oxalate intake. One group added wheat bran to their diet. All participants were administered hydrochlorothiazide (50 mg/12 h) and potassium citrate (5 mEq/8 h) over the following week.</LI>
<LI>
<LINK REF="STD-Nishiura-2004" TYPE="STUDY">Nishiura 2004</LINK> (20/69 idiopathic hypercalciuria participants) prospectively evaluated <I>P. niruri</I> plant substrate intake on 24 hour urinary biochemical parameters to assess in vivo effects. The study's 20 participants with idiopathic hypercalciuria were randomised to receive either <I>P. niruri</I> (8) (450 mg capsules three times/d) or placebo (12) for three months. Dietetic and pharmacological co-interventions were not specified in the report.</LI>
<LI>
<LINK REF="STD-Coe-1992" TYPE="STUDY">Coe 1992</LINK> (12 participants) evaluated changes in urinary supersaturation in healthy, non-stone-forming participants with who consumed calcium-fortified orange juice or milk in a cross-over study over four weeks. Participants followed a free diet that included a calcium supplement (600 mg/d) administered as skim milk or orange juice fortified with calcium-citrate-malate salt.</LI>
</UL>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2014-02-04 14:19:35 +1100" MODIFIED_BY="[Empty name]">
<P>We excluded 18 studies (22 records) after full-text assessment: four were not RCTs (<LINK REF="STD-Colette-1993" TYPE="STUDY">Colette 1993</LINK>; <LINK REF="STD-Jaeger-1982" TYPE="STUDY">Jaeger 1982</LINK>; <LINK REF="STD-Muller-2001" TYPE="STUDY">Muller 2001</LINK>; <LINK REF="STD-Schwille-1997" TYPE="STUDY">Schwille 1997</LINK>); seven investigated populations that were not relevant to this review (<LINK REF="STD-Aras-2008" TYPE="STUDY">Aras 2008</LINK>; <LINK REF="STD-Baxmann-2003" TYPE="STUDY">Baxmann 2003</LINK>; <LINK REF="STD-Bellizzi-1999" TYPE="STUDY">Bellizzi 1999</LINK>; <LINK REF="STD-Domrongkitchaiporn-2004" TYPE="STUDY">Domrongkitchaiporn 2004</LINK>; <LINK REF="STD-Lamid-1984" TYPE="STUDY">Lamid 1984</LINK>; <LINK REF="STD-Matsumoto-2006" TYPE="STUDY">Matsumoto 2006</LINK>; <LINK REF="STD-van-Faassen-1998" TYPE="STUDY">van Faassen 1998</LINK>); one investigated an intervention not relevant to this review (<LINK REF="STD-Ala_x002d_Opas-1987" TYPE="STUDY">Ala-Opas 1987</LINK>); and relevant subgroup data analyses were not available in six papers (<LINK REF="STD-Borghi-1996" TYPE="STUDY">Borghi 1996</LINK>; <LINK REF="STD-Campoy-Martinez-1994" TYPE="STUDY">Campoy Martinez 1994</LINK>; <LINK REF="STD-Hiatt-1996" TYPE="STUDY">Hiatt 1996</LINK>; <LINK REF="STD-Karagulle-2007" TYPE="STUDY">Karagulle 2007</LINK>; <LINK REF="STD-Kocvara-1999" TYPE="STUDY">Kocvara 1999</LINK>; <LINK REF="STD-Rotily-2000" TYPE="STUDY">Rotily 2000</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-02-04 14:33:54 +1100" MODIFIED_BY="[Empty name]">
<P>Overall, study methodology was not adequately reported in any of the included studies (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). There was a high risk of bias associated with blinding (although it seems unlikely that outcomes measures were unduly influenced by lack of intervention blinding), random sequence generation and allocation methodologies were unclear in most studies, but selective reporting bias was assessed as low.</P>
<ALLOCATION MODIFIED="2014-01-29 10:27:35 +1100" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Borghi-2002" TYPE="STUDY">Borghi 2002</LINK> and <LINK REF="STD-Nouvenne-2010" TYPE="STUDY">Nouvenne 2010</LINK> adequately described sequence generation of participant randomisation and allocation; <LINK REF="STD-Coe-1992" TYPE="STUDY">Coe 1992</LINK>, <LINK REF="STD-Gleeson-1990" TYPE="STUDY">Gleeson 1990</LINK> and <LINK REF="STD-Nishiura-2004" TYPE="STUDY">Nishiura 2004</LINK> did not specify randomisation methods applied.</P>
</ALLOCATION>
<BLINDING MODIFIED="2013-03-28 14:14:11 +1100" MODIFIED_BY="[Empty name]">
<P>Only <LINK REF="STD-Nishiura-2004" TYPE="STUDY">Nishiura 2004</LINK> adequately described blinding of participants. The nature of the interventions meant that participants were not blinded in <LINK REF="STD-Borghi-2002" TYPE="STUDY">Borghi 2002</LINK>, <LINK REF="STD-Coe-1992" TYPE="STUDY">Coe 1992</LINK>, <LINK REF="STD-Gleeson-1990" TYPE="STUDY">Gleeson 1990</LINK> or <LINK REF="STD-Nouvenne-2010" TYPE="STUDY">Nouvenne 2010</LINK>; however, it is unlikely that outcome measures were influenced by lack of blinding.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2014-02-04 14:33:54 +1100" MODIFIED_BY="[Empty name]">
<P>Follow-up was complete, or near complete in <LINK REF="STD-Borghi-2002" TYPE="STUDY">Borghi 2002</LINK> and <LINK REF="STD-Nouvenne-2010" TYPE="STUDY">Nouvenne 2010</LINK>. <LINK REF="STD-Borghi-2002" TYPE="STUDY">Borghi 2002</LINK> reported that 17 participants (14%) withdrew from the study. <LINK REF="STD-Nouvenne-2010" TYPE="STUDY">Nouvenne 2010</LINK> reported that 13 participants withdrew: two in Group A (due to work problems to assist visits) and 11 in Group B (due to adaptation problems to low salt diet). <LINK REF="STD-Coe-1992" TYPE="STUDY">Coe 1992</LINK>, <LINK REF="STD-Gleeson-1990" TYPE="STUDY">Gleeson 1990</LINK> and <LINK REF="STD-Nishiura-2004" TYPE="STUDY">Nishiura 2004</LINK> did not report attrition rates.</P>
</EXCLUSIONS>
<OTHER_BIAS_SOURCES MODIFIED="2014-01-29 10:30:27 +1100" MODIFIED_BY="[Empty name]">
<P>A pharmacological co-intervention was included at the end of one study (<LINK REF="STD-Gleeson-1990" TYPE="STUDY">Gleeson 1990</LINK>). In <LINK REF="STD-Nishiura-2004" TYPE="STUDY">Nishiura 2004</LINK> possible differences in co-interventions between groups were not excluded. <LINK REF="STD-Nouvenne-2010" TYPE="STUDY">Nouvenne 2010</LINK> was conducted in participants having a special baseline characteristic (high salt content diet intake).</P>
<P>No other potential threats to validity were detected.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-02-06 08:08:54 +1100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Low calcium diet versus normal calcium, low protein, low salt diet</HEADING>
<P>Only <LINK REF="STD-Borghi-2002" TYPE="STUDY">Borghi 2002</LINK> could be analysed for this intervention. <LINK REF="STD-Gleeson-1990" TYPE="STUDY">Gleeson 1990</LINK> investigated reduced calcium and oxalate intake; however, both groups followed similar calcium restricted diets, so comparison could not be made. <LINK REF="STD-Nouvenne-2010" TYPE="STUDY">Nouvenne 2010</LINK> investigated reduced salt and normal calcium diets, but analyses of protein intake were not provided and because calcium intake was not controlled; outcomes were therefore not comparable.</P>
<SUBSECTION>
<HEADING LEVEL="4">Kidney stones</HEADING>
<P>We assessed the total number of patients reported by <LINK REF="STD-Borghi-2002" TYPE="STUDY">Borghi 2002</LINK> who had no new recurrences during follow-up. This study found a significant decrease among those assigned to the normal calcium, low protein, low salt diet (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK> (1 study, 120 participants): RR 0.77, 95% CI 0.61 to 0.98). We were unable to determine the numbers of kidney stone recurrences to establish the stone formation rate because participants were excluded as they experienced stone events.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Urinary metabolite levels</HEADING>
<P>At one week <LINK REF="STD-Borghi-2002" TYPE="STUDY">Borghi 2002</LINK> reported a decrease in calciuria in the normal calcium, low protein, low salt diet participants (6.1 ± 2.2 versus 8.3 ± 3.4). However, the effect was not sustained; there was no significant decrease in calciuria at five years (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK> (1 study, 68 participants): MD 0.30 mmol/d, 95% CI -0.57 to 0.1.17).</P>
<P>In contrast, effects of the normal calcium, low protein low salt diet on oxalate daily urinary excretion was sustained. Oxaluria decreased significantly in this group compared with low calcium diet group at five years (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK> (1 study, 68 participants): MD 78.00 µmol/d, 95% CI 26.48 to 129.52). Calcium oxalate relative supersaturation index decreased significantly throughout the study, reflecting a decrease in the risk of urinary crystallisation, and possibly an indirect decrease in the risk of urinary stones in the low calcium diet group (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK> (1 study, 68 participants): MD 1.20, 95% CI 0.21 to 2.19).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other results</HEADING>
<P>No metabolic or gastrointestinal side effects were described. Seven low calcium intake participants withdrew because of hypertension - a possible adverse effect of low calcium intake. We therefore analysed blood pressure changes in both groups during follow-up; no significant differences were determined (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK> (1 study, 120 participants): RR 7.00, 95% CI 0.89 to 55.17).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Low salt, normal calcium diet versus a normal salt diet</HEADING>
<P>
<LINK REF="STD-Nouvenne-2010" TYPE="STUDY">Nouvenne 2010</LINK> investigated the effects of a low salt, normal calcium diet on 210 people with histories of calcium stone formation for three months. This study reported low salt diet group participants had lower urinary sodium (68 ± 43 mmol/d at three months versus 228 ± 57 mmol/d at baseline, P &lt; 0.001). This group also showed a significantly lower level of urinary calcium compared with normal salt diet group (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK> (1 study, 210 participants): MD -45.00 mg/d, 95% CI -74.83 to -15.17) as well as a significantly lower oxalate excretion (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK> (1 study, 210 participants): MD - 4.00 mg/d, 95% CI -6.44 to -1.56) at three months. When expressed in relation to a sodium diet reduction of 100 mmol, calcium excretion decreased by approximately 64 mg/100 mmol sodium. Urinary calcium was within the normal range in 61.9% of low salt, normal calcium diet participants and 34.0% on the control diet (difference + 27.9%, 95% CI 14.4% to 41.3%, P &lt; 0.001).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Phyllanthus niruri versus placebo</HEADING>
<P>
<LINK REF="STD-Nishiura-2004" TYPE="STUDY">Nishiura 2004</LINK> assessed <I>P. niruri,</I> a plant used in Brazil to treat urinary calculi, to investigate its effect in reducing lithogenic metabolic urinary abnormalities. <I>P. niruri</I> was compared to placebo over three months in a subgroup of 20 participants with idiopathic hypercalciuria. Although people treated with the plant extract had significantly reduced calciuria compared with baseline values, there was no significant difference between groups at the end of follow-up (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK> (1 study, 20 participants): MD -1.10 mg/kg/d, 95% CI -2.37 to 0.17). Serum biochemical parameters were not significantly different following <I>P. niruri</I> or placebo administration.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Unprocessed wheat bran</HEADING>
<P>
<LINK REF="STD-Gleeson-1990" TYPE="STUDY">Gleeson 1990</LINK> analysed the hypocalciuric effect of dietary fibre added to a low calcium, low oxalate diet for a period of three weeks in 17 people with idiopathic hypercalciuria. Calciuria decreased significantly in the unprocessed wheat bran group (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK> (1 study, 17 participants): MD -64.80 mg/d, 95% CI -98.94 to -30.66). The daily additional dietary fibre contained 164 mg of oxalate, so the treatment group received an oxalate-enriched diet. As expected, oxalate increased significantly in the unprocessed wheat bran group (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK> (1 study, 17 participants): MD 13.70 mg/d, 95% CI 8.37 to 19.03). The overall effect on the risk of urinary crystallisation was therefore uncertain.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Calcium-fortified orange juice and milk</HEADING>
<P>
<LINK REF="STD-Coe-1992" TYPE="STUDY">Coe 1992</LINK> evaluated milk and orange juice fortified with calcium citrate malate for potential to alter urine chemistries and crystallisation during an 11 week cross-over study (12 participants). Results were analysed by gender (M/F: 6/6). Daily urinary calcium excretion was not significantly affected by either supplement in either gender. Supplementary calcium (600 mg) did not increase calciuria from baseline (241 ± 30 mg/d versus 234 ± 16 mg/d in men, and 180 ± 20 mg/d versus 216 ± 11 mg/d in women for the milk supplement; and 241 ± 30 mg/d versus 242 ± 16 mg/d in men and 180 ± 20 mg/d versus 214 ± 15 mg/d in women for orange juice supplement).</P>
<P>Fortified orange juice significantly increased urinary pH relative to milk in both men and women (6.22 ± 0.09 versus 8.96 ± 0.08 in men and 6.54 ± 0.08 versus 6.24 ± 0.10 in women) and urinary citrate concentration in women only (540 ± 57 mg/L versus 358 ± 31 mg/L); no difference in daily citrate excretion was observed. Both urinary parameters were significantly increased by orange juice in both men and women relative to baseline (544 ± 46 mg/d versus 517 ± 49 mg/d in men and 689 ± 30 mg/d versus 515 ± 47 mg/d in women).</P>
<P>Urinary relative supersaturation indices for calcium oxalate, brushite and calcium carbonate did not vary significantly between dietary supplements. The calcium carbonate supersaturating index increased significantly in groups who received supplements relative to baseline values.</P>
<P>Due to the small number of studies identified we were unable to perform subgroup analyses to investigate heterogeneity, perform sensitivity analyses, assess publication biases, or tabulate adverse events as stated in our protocol.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-02-06 08:08:54 +1100" MODIFIED_BY="[Empty name]">
<P>This review identified five studies (379 participants) that assessed the effects of different dietary interventions to prevent complications in people with idiopathic hypercalciuria. Overall, the included studies were assessed as moderate methodological quality and risk of bias.</P>
<P>We were unable to conduct meta-analysis because of lack of similarity among interventions which did not permit the data to be pooled. Furthermore, we found no studies that investigated dietary interventions among children with hypercalciuria, or that analysed the effect of an isolated reduction of dietary calcium on stone recurrence in people with hypercalciuria.</P>
<P>Although, none of the studies reported any significant adverse effects associated with the dietary interventions investigated, no compelling evidence was identified to support the use of dietary interventions to reduce the risk of complications among people with idiopathic hypercalciuria.</P>
<SUMMARY_OF_RESULTS MODIFIED="2014-02-06 08:08:54 +1100" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Borghi-2002" TYPE="STUDY">Borghi 2002</LINK> compared low calcium diet with normal calcium, low protein, low salt diet for five years. There was a significant decrease in numbers of new stone recurrences in those who followed normal calcium, low protein, low salt diets (RR 0.77, 95% CI 0.61 to 0.98). People on this diet also had significant decreases in oxaluria and in the calcium oxalate relative supersaturation index.</P>
<P>
<LINK REF="STD-Borghi-2002" TYPE="STUDY">Borghi 2002</LINK> compared a broad diet that included normal intake of calcium but low levels of sodium and protein, with a calcium-restricted diet for people with hypercalciuria who had histories of kidney stones. Urinary calcium was reduced in participants who adopted the broad diet in the short term, but this effect was not maintained over time. However, participants on the broad diet achieved consistent and permanent decreased oxaluria (MD 78 µmol/d), which improved calcium oxalate relative supersaturation index in urine for prolonged periods of time.</P>
<P>Isolated reduction of dietary calcium was less efficient than reducing sodium and protein combined with higher calcium intake. Although this diet was effective in controlling urinary metabolites in people with hypercalciuria, it could not be determined which aspects of the broad diet were most significant.</P>
<P>
<LINK REF="STD-Nouvenne-2010" TYPE="STUDY">Nouvenne 2010</LINK> compared a low salt, normal calcium diet with an unrestricted diet over three months. The unrestricted diet decreased urinary calcium (MD -45.00 mg/d, 95% CI -74.83 to -15.17) and oxalate excretion (MD -4.00 mg/d, 95% CI -6.44 to -1.56).</P>
<P>
<LINK REF="STD-Gleeson-1990" TYPE="STUDY">Gleeson 1990</LINK> investigated inclusion of unprocessed wheat bran to a low calcium, low oxalate diet for three weeks. Dietary fibre was found to reduce calciuria (MD -64.80 mg/d), possibly by affecting calcium absorption. Reduction from baseline was 23%. However, unprocessed wheat bran is rich in oxalate, and caused increased oxaluria despite the base diet being low in oxalates. The overall effect on risk of stone development is controversial: the control group received a low calcium, low oxalate diet, with little positive effect on calciuria reduction.</P>
<P>
<LINK REF="STD-Nishiura-2004" TYPE="STUDY">Nishiura 2004</LINK> investigated the effect of <I>P. niruri </I>plant extract on 24 hour urinary biochemical parameters in a small subgroup with hypercalciuria. No significant effect on calciuria levels occurred after three months of treatment.</P>
<P>
<LINK REF="STD-Coe-1992" TYPE="STUDY">Coe 1992</LINK> evaluated dietary intake of 600 mg of calcium/d as skim milk or orange juice fortified with a mixed calcium citrate malate salt over four consecutive weeks. Compared with milk, fortified orange juice had no effect on urine chemistries in hypercalciuric adults, except that urine pH and citrate excretion increased. Theoretically, these changes prevent increases in the calcium oxalate supersaturation index, but study data did not demonstrate differences in calcium oxalate, brushite or calcium carbonate supersaturation indices. Thus, both beverage supplements had similar efficacies. Furthermore, neither supplement changed urinary calcium nor oxalate excretion levels with respect to baseline. These data indicate that either milk or calcium-fortified orange juice can be consumed as a dietary source of calcium without increasing the risk of stone formation in a hypercalciuric population. Because the study design did not enable clear comparison between non-restricted and calcium-supplemented diets or sources of calcium supplementation, these data should be interpreted cautiously. The study found no benefits for participants.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2014-02-04 11:30:30 +1100" MODIFIED_BY="[Empty name]">
<P>We assessed five RCTs that investigated dietary interventions for preventing complications among people with idiopathic hypercalciuria. We were unable to obtain data relating to all pre-defined outcome measures because they were not all reported in the included studies.</P>
<P>Reporting in the included studies was suboptimal. Only two studies adequately reported adverse events and drop-outs.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2014-02-04 11:17:26 +1100" MODIFIED_BY="[Empty name]">
<P>Overall, the quality of the evidence supporting dietary interventions is poor, since study methodology was not adequately reported in the included studies and only one study had low risk on most sources of bias.</P>
</QUALITY_OF_EVIDENCE>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-02-04 18:56:43 +1100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2014-02-04 18:56:36 +1100" MODIFIED_BY="[Empty name]">
<P>We found limited and methodologically flawed evidence that compared with other diet-based strategies, prolonged normal calcium, low protein, low sodium diets may reduce numbers of stone recurrences in people with idiopathic hypercalciuria.</P>
<P>Limited quality evidence was also identified indicating that normal calcium, low protein, low sodium diets may decrease oxaluria and the calcium oxalate relative supersaturation index in people with symptomatic idiopathic hypercalciuria, without significant adverse effects.</P>
<P>Limited suboptimal evidence also indicated that compared with other dietary interventions, low sodium, normal calcium diet may reduce calciuria and oxaluria in people with idiopathic hypercalciuria and recurrent stones for some months.</P>
<P>Limited and flawed evidence suggested that including unprocessed wheat bran in the diet for short periods may reduce calciuria but increases oxaluria in people with idiopathic hypercalciuria.</P>
<P>We found no evidence to support that dietary interventions were beneficial in preventing formation of stones in people with asymptomatic idiopathic hypercalciuria.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-02-04 18:56:43 +1100" MODIFIED_BY="[Empty name]">
<P>Although there is limited evidence to suggest that normal calcium, low protein, low sodium diets over long periods may reduce numbers of stone recurrences and decrease urinary calcium oxalate supersaturation indices in men who are hypercalciuric, further well-designed, adequately powered studies are needed to evaluate effects on bone health. Future investigators should also consider designing parallel studies to assess other broad and inclusive dietary interventions with normal calcium, low protein, low sodium diets.</P>
<P>Larger studies over longer periods are required to investigate if low sodium and normal calcium diets can improve urinary calcium oxalate supersaturation indices in people with hypercalciuria to reduce numbers of stone recurrences and establish impact on bone health.</P>
<P>Well-designed, adequately powered, studies in children with idiopathic hypercalciuria are needed to determine if normal calcium, low sodium, low protein and high fluid diets can reduce urologic symptoms, kidney stone recurrence and improve bone health.</P>
<P>Well-designed RCTs are required to evaluate whether diet can reduce development of kidney stones and maintain bone health in adults and children with asymptomatic hypercalciuria.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-01-03 04:48:40 +1100" MODIFIED_BY="Narelle S Willis">
<P>We would like to thank the referees for their feedback and advice during the preparation of this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-03-27 12:30:07 +1100" MODIFIED_BY="[Empty name]">
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-01-28 02:12:51 +1100" MODIFIED_BY="[Empty name]">
<P>Writing protocol and review: JE, AF, AB, NF, MR<BR/>Screening titles and abstracts: JE, AF, AB, NF, MR<BR/>Assessment for inclusion: JE, AF, AB, NF, MR<BR/>Quality assessment: JE, AF, AB, NF, MR<BR/>Data extraction: JE, AF, AB, NF<BR/>Data entry into RevMan: JE<BR/>Data analysis: JE, AB, MR<BR/>Disagreement resolution: MR</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES MODIFIED="2008-07-07 10:44:18 +1000" MODIFIED_BY="Narelle S Willis"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-02-06 08:12:05 +1100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2014-02-04 14:19:35 +1100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2013-12-27 15:19:21 +1100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Borghi-2002" MODIFIED="2013-12-27 15:15:40 +1100" MODIFIED_BY="[Empty name]" NAME="Borghi 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-12-27 15:15:40 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Borghi L, Schianchi T, Meschi T, Guerra A, Allegri F, Maggiore U, et al</AU>
<TI>Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria</TI>
<SO>New England Journal of Medicine</SO>
<YR>2002</YR>
<VL>346</VL>
<NO>2</NO>
<PG>77-84</PG>
<IDENTIFIERS MODIFIED="2013-12-27 15:15:40 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 15:15:40 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11784873"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coe-1992" MODIFIED="2013-12-27 15:16:18 +1100" MODIFIED_BY="[Empty name]" NAME="Coe 1992" YEAR="1992">
<REFERENCE MODIFIED="2013-12-27 15:16:18 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coe FL, Parks JH, Webb DR</AU>
<TI>Stone-forming potential of milk or calcium-fortified orange juice in idiopathic hypercalciuric adults</TI>
<SO>Kidney International</SO>
<YR>1992</YR>
<VL>41</VL>
<NO>1</NO>
<PG>139-42</PG>
<IDENTIFIERS MODIFIED="2013-12-27 15:16:18 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 15:16:18 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="1593849"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gleeson-1990" MODIFIED="2013-12-27 15:16:54 +1100" MODIFIED_BY="[Empty name]" NAME="Gleeson 1990" YEAR="1990">
<REFERENCE MODIFIED="2013-12-27 15:16:54 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gleeson MJ, Thompson AS, Mehta S, Griffith DP</AU>
<TI>Effect of unprocessed wheat bran on calciuria and oxaluria in patients with urolithiasis</TI>
<SO>Urology</SO>
<YR>1990</YR>
<VL>35</VL>
<NO>3</NO>
<PG>231-4</PG>
<IDENTIFIERS MODIFIED="2013-12-27 15:16:54 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 15:16:54 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="2156368"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nishiura-2004" MODIFIED="2013-12-27 15:18:13 +1100" MODIFIED_BY="[Empty name]" NAME="Nishiura 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-12-27 15:18:13 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nishiura JL, Campos AH, Boim MA, Heilberg IP, Schor N</AU>
<TI>Phyllanthus niruri normalizes elevated urinary calcium levels in calcium stone forming (CSF) patients</TI>
<SO>Urological Research</SO>
<YR>2004</YR>
<VL>32</VL>
<NO>5</NO>
<PG>362-6</PG>
<IDENTIFIERS MODIFIED="2013-12-27 15:18:13 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 15:18:13 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15221244"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nouvenne-2010" MODIFIED="2013-12-27 15:19:21 +1100" MODIFIED_BY="[Empty name]" NAME="Nouvenne 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-12-27 15:19:21 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nouvenne A, Meschi T, Prati B, Guerra A, Allegri F, Vezzoli G, et al</AU>
<TI>Effects of a low-salt diet on idiopathic hypercalciuria in calcium-oxalate stone formers: a 3-mo randomized controlled trial</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2010</YR>
<VL>91</VL>
<NO>3</NO>
<PG>565-70</PG>
<IDENTIFIERS MODIFIED="2013-12-27 15:19:21 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 15:19:21 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="20042524"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-02-04 14:19:35 +1100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Ala_x002d_Opas-1987" MODIFIED="2013-12-27 15:19:58 +1100" MODIFIED_BY="[Empty name]" NAME="Ala-Opas 1987" YEAR="1987">
<REFERENCE MODIFIED="2013-12-27 15:19:58 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ala-Opas M, Elomaa I, Porkka L, Alfthan O</AU>
<TI>Unprocessed bran and intermittent thiazide therapy in prevention of recurrent urinary calcium stones</TI>
<SO>Scandinavian Journal of Urology &amp; Nephrology</SO>
<YR>1987</YR>
<VL>21</VL>
<NO>4</NO>
<PG>311-4</PG>
<IDENTIFIERS MODIFIED="2013-12-27 15:19:58 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 15:19:58 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="2832935"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aras-2008" MODIFIED="2013-12-27 15:21:11 +1100" MODIFIED_BY="[Empty name]" NAME="Aras 2008" YEAR="2008 Dec">
<REFERENCE MODIFIED="2013-12-27 15:21:11 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aras B, Kalfazade N, Tugcu V, Kemahli E, Ozbay B, Polat H, et al</AU>
<TI>Can lemon juice be an alternative to potassium citrate in the treatment of urinary calcium stones in patients with hypocitraturia? A prospective randomized study</TI>
<SO>Urological Research</SO>
<YR>2008</YR>
<VL>36</VL>
<NO>6</NO>
<PG>313-7</PG>
<IDENTIFIERS MODIFIED="2013-12-27 15:21:11 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 15:21:11 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18946667"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baxmann-2003" MODIFIED="2013-12-27 15:24:51 +1100" MODIFIED_BY="[Empty name]" NAME="Baxmann 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-12-27 15:24:51 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baxmann AC, De O G Mendonca C, Heilberg IP</AU>
<TI>Effect of vitamin C supplements on urinary oxalate and pH in calcium stone-forming patients</TI>
<SO>Kidney International</SO>
<YR>2003</YR>
<VL>63</VL>
<NO>3</NO>
<PG>1066-71</PG>
<IDENTIFIERS MODIFIED="2013-12-27 15:24:51 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 15:24:51 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12631089"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bellizzi-1999" MODIFIED="2013-12-27 15:26:34 +1100" MODIFIED_BY="[Empty name]" NAME="Bellizzi 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-12-27 15:26:34 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bellizi V, De Nicola L, Minutolo R, Russo D, Cianciaruso B, Andreucci M, et al</AU>
<TI>Effects of water hardness on urinary risk factors for kidney stones</TI>
<SO>Nephron</SO>
<YR>1999</YR>
<VL>81 Suppl 1</VL>
<PG>66-70</PG>
<IDENTIFIERS MODIFIED="2013-12-27 15:26:26 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 15:26:26 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="9873217"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Borghi-1996" MODIFIED="2013-12-27 15:27:48 +1100" MODIFIED_BY="[Empty name]" NAME="Borghi 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-12-27 15:27:48 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Borghi L, Meschi T, Amato F, Briganti A, Novarini A, Giannini A</AU>
<TI>Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study</TI>
<SO>Journal of Urology</SO>
<YR>1996</YR>
<VL>155</VL>
<NO>3</NO>
<PG>839-43</PG>
<IDENTIFIERS MODIFIED="2013-12-27 15:27:48 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 15:27:48 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="8583588"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Campoy-Martinez-1994" MODIFIED="2013-12-27 15:49:29 +1100" MODIFIED_BY="[Empty name]" NAME="Campoy Martinez 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-12-27 15:48:46 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Campoy Martinez P, Arrabal Martin M, Blasco Hernandez P, Silva Mejias C, Reina Ruiz C, Espinosa Olmedo FJ, et al</AU>
<TI>Orange juice in oxalocalcic lithiasis prevention</TI>
<TO>Zumo de naranja en la prevención de la litiasis oxalocalcica</TO>
<SO>Actas Urologicas Espanolas</SO>
<YR>1994</YR>
<VL>18</VL>
<NO>7</NO>
<PG>738-43</PG>
<IDENTIFIERS MODIFIED="2013-12-27 15:48:46 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 15:48:46 +1100" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="CN-00105619"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Colette-1993" MODIFIED="2013-12-27 15:34:07 +1100" MODIFIED_BY="[Empty name]" NAME="Colette 1993" YEAR="1993">
<REFERENCE MODIFIED="2013-12-27 15:34:07 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Colette C, Percheron C, Thanh C, Boniface H, Thomas N, Guiter J, et al</AU>
<TI>Renal handling of calcium in hypercalciuric calcium oxalate nephrolithiasis</TI>
<SO>Mineral &amp; Electrolyte Metabolism</SO>
<YR>1993</YR>
<VL>19</VL>
<NO>6</NO>
<PG>377-84</PG>
<IDENTIFIERS MODIFIED="2013-12-27 15:34:07 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 15:34:07 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="8164620"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Domrongkitchaiporn-2004" MODIFIED="2013-12-27 15:34:41 +1100" MODIFIED_BY="[Empty name]" NAME="Domrongkitchaiporn 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-12-27 15:34:41 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Domrongkitchaiporn S, Sopassathit W, Stitchantrakul W, Prapaipanich S, Ingsathit A, Rajatanavin R</AU>
<TI>Schedule of taking calcium supplement and the risk of nephrolithiasis</TI>
<SO>Kidney International</SO>
<YR>2004</YR>
<VL>65</VL>
<NO>5</NO>
<PG>1835-41</PG>
<IDENTIFIERS MODIFIED="2013-12-27 15:34:41 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 15:34:41 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15086924"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hiatt-1996" MODIFIED="2013-12-27 15:35:19 +1100" MODIFIED_BY="[Empty name]" NAME="Hiatt 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-12-27 15:35:19 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hiatt RA, Ettinger B, Caan B, Quesenberry CP Jr, Duncan D, Citron JT</AU>
<TI>Randomized controlled trial of a low animal protein, high fiber diet in the prevention of recurrent calcium oxalate kidney stones</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1996</YR>
<VL>144</VL>
<NO>1</NO>
<PG>25-33</PG>
<IDENTIFIERS MODIFIED="2013-12-27 15:35:19 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 15:35:19 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="8659482"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jaeger-1982" MODIFIED="2013-12-27 15:36:24 +1100" MODIFIED_BY="[Empty name]" NAME="Jaeger 1982" YEAR="1982">
<REFERENCE MODIFIED="2013-12-27 15:36:24 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jaeger P, Portmann L, Bugnon JM, Jacquet AF, Burckhardt P</AU>
<TI>Incidence of hyperoxaluria in idiopathic calcium nephrolithiasis</TI>
<TO>Incidence de l'hyperoxalurie dans la lithiase renale calcique idiopathique</TO>
<SO>Schweizerische Medizinische Wochenschrift. Journal Suisse de Medecine</SO>
<YR>1982</YR>
<VL>112</VL>
<NO>49</NO>
<PG>1795-8</PG>
<IDENTIFIERS MODIFIED="2013-12-27 15:36:22 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 15:36:22 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="7178877"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karagulle-2007" MODIFIED="2014-02-04 14:19:35 +1100" MODIFIED_BY="[Empty name]" NAME="Karagulle 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-12-27 15:37:13 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karagulle O, Smorag U, Candir F, Gundermann G, Jonas U, Becker AJ, et al</AU>
<TI>Clinical study on the effect of mineral waters containing bicarbonate on the risk of urinary stone formation in patients with multiple episodes of CaOx-urolithiasis</TI>
<SO>World Journal of Urology</SO>
<YR>2007</YR>
<VL>25</VL>
<NO>3</NO>
<PG>315-23</PG>
<IDENTIFIERS MODIFIED="2013-12-27 15:37:11 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 15:37:11 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17333204"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kocvara-1999" MODIFIED="2013-12-27 15:37:50 +1100" MODIFIED_BY="[Empty name]" NAME="Kocvara 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-12-27 15:37:50 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kocvara R, Plasgura P, Petrik A, Louzensky G, Bartonickova K, Dvoracek J</AU>
<TI>A prospective study of nonmedical prophylaxis after a first kidney stone</TI>
<SO>BJU International</SO>
<YR>1999</YR>
<VL>84</VL>
<NO>4</NO>
<PG>393-8</PG>
<IDENTIFIERS MODIFIED="2013-12-27 15:37:50 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 15:37:50 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="10468751"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lamid-1984" MODIFIED="2013-12-27 15:38:31 +1100" MODIFIED_BY="[Empty name]" NAME="Lamid 1984" YEAR="1984">
<REFERENCE MODIFIED="2013-12-27 15:38:31 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lamid S, El Ghatit AZ, Melvin JL</AU>
<TI>Relationship of hypercalciuria to diet and bladder stone formation in spinal cord injury patients</TI>
<SO>American Journal of Physical Medicine</SO>
<YR>1984</YR>
<VL>63</VL>
<NO>4</NO>
<PG>182-7</PG>
<IDENTIFIERS MODIFIED="2013-12-27 15:38:31 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 15:38:31 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="6380301"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matsumoto-2006" MODIFIED="2013-12-27 15:39:11 +1100" MODIFIED_BY="[Empty name]" NAME="Matsumoto 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-12-27 15:39:11 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matsumoto ED, Heller HJ, Adams-Huet B, Brinkley LJ, Pak CY, Pearle MS</AU>
<TI>Effect of high and low calcium diets on stone forming risk during liberal oxalate intake</TI>
<SO>Journal of Urology</SO>
<YR>2006</YR>
<VL>176</VL>
<NO>1</NO>
<PG>132-6</PG>
<IDENTIFIERS MODIFIED="2013-12-27 15:39:11 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 15:39:11 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16753387"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muller-2001" MODIFIED="2014-01-29 09:36:35 +1100" MODIFIED_BY="[Empty name]" NAME="Muller 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-12-27 15:39:44 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Muller D, Eggert P</AU>
<TI>Prolonged dietary calcium restriction: a diagnostic approach in idiopathic hypercalciuria</TI>
<SO>Nephron</SO>
<YR>2001</YR>
<VL>89</VL>
<NO>4</NO>
<PG>384-90</PG>
<IDENTIFIERS MODIFIED="2013-12-27 15:39:44 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 15:39:44 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11721154"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rotily-2000" MODIFIED="2014-01-29 09:39:29 +1100" MODIFIED_BY="[Empty name]" NAME="Rotily 2000" YEAR="2000">
<REFERENCE MODIFIED="2014-01-29 09:38:19 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berland Y, Leonetti F, Rotily M, Iovanna C, Berthezene P, Dupuy P, et al</AU>
<TI>Low protein and high fiber diets do not affect the risk of idiopathic calcium stones [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1999</YR>
<VL>14</VL>
<NO>9</NO>
<PG>A32</PG>
<IDENTIFIERS MODIFIED="2014-01-29 09:38:19 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-01-29 09:38:19 +1100" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="CN-00483207"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-27 15:41:44 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dussol B, Iovanna C, Rotily M, Morange S, Leonetti F, Dupuy P, et al</AU>
<TI>A randomized trial of low-animal-protein or high-fiber diets for secondary prevention of calcium nephrolithiasis</TI>
<SO>Nephron</SO>
<YR>2008</YR>
<VL>110</VL>
<NO>3</NO>
<PG>c185-94</PG>
<IDENTIFIERS MODIFIED="2013-12-27 15:41:44 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 15:41:44 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18957869"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-29 09:38:58 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dussol B, Saveanu A, Leonetti F, Iovanna C, Morange S, Rotily M, et al</AU>
<TI>A 4-year randomized controlled trial of low animal protein or high-fiber diets for secondary prevention of idiopathic calcium nephrolithiasis [abstract no: TH-F-DS876]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2006</YR>
<VL>17</VL>
<NO>Abstracts</NO>
<PG>521A</PG>
<IDENTIFIERS MODIFIED="2014-01-29 09:38:50 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-01-29 09:38:50 +1100" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="CN-00688833"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-29 09:39:29 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dussol B, Saveanu A, Rotily M, Morange S, Leonetti F, Berland Y</AU>
<TI>Effects of low-animal protein or high-fiber diets on urine composition in calcium nephrolithiasis [abstract no: PUB452]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>Oct</NO>
<PG>857A</PG>
<IDENTIFIERS MODIFIED="2014-01-29 09:39:23 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-01-29 09:39:23 +1100" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="CN-00583506"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-27 15:44:20 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rotily M, Leonetti F, Iovanna C, Berthezene P, Dupuy P, Vazi A, et al</AU>
<TI>Effects of low animal protein or high-fiber diets on urine composition in calcium nephrolithiasis</TI>
<SO>Kidney International</SO>
<YR>2000</YR>
<VL>57</VL>
<NO>3</NO>
<PG>1115-23</PG>
<IDENTIFIERS MODIFIED="2013-12-27 15:44:20 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 15:44:20 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="10720964"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schwille-1997" MODIFIED="2013-12-27 15:50:01 +1100" MODIFIED_BY="[Empty name]" NAME="Schwille 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-12-27 15:50:01 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schwille PO, Herrmann U, Schmiedl A, Kissler H, Wipplinger J, Manoharan M</AU>
<TI>Urinary phosphate excretion in the pathophysiology of idiopathic recurrent calcium urolithiasis: hormonal interactions and lipid metabolism</TI>
<SO>Urological Research</SO>
<YR>1997</YR>
<VL>25</VL>
<NO>6</NO>
<PG>417-26</PG>
<IDENTIFIERS MODIFIED="2013-12-27 15:50:01 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 15:50:01 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="9443652"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Faassen-1998" MODIFIED="2013-12-27 15:45:37 +1100" MODIFIED_BY="[Empty name]" NAME="van Faassen 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-12-27 15:45:37 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Faassen A, van der Ploeg EM, Habets HM, van der Meer R, Hermus RJ, Janknegt RA</AU>
<TI>The effects of the calcium-restricted diet of urolithiasis patients with absorptive hypercalciuria type II on risk factors for kidney stones and osteopenia</TI>
<SO>Urological Research</SO>
<YR>1998</YR>
<VL>26</VL>
<NO>1</NO>
<PG>65-9</PG>
<IDENTIFIERS MODIFIED="2013-12-27 15:45:37 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 15:45:37 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="9537699"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2013-04-23 15:00:02 +1000" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-02-06 08:12:05 +1100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2014-02-04 14:30:33 +1100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Asplin-2003" MODIFIED="2013-12-27 15:51:58 +1100" MODIFIED_BY="[Empty name]" NAME="Asplin 2003" TYPE="JOURNAL_ARTICLE">
<AU>Asplin JR, Bauer KA, Kinder J, Muller G, Coe BJ, Parks JH, et al</AU>
<TI>Bone mineral density and urine calcium excretion among subjects with and without nephrolithiasis</TI>
<SO>Kidney International</SO>
<YR>2003</YR>
<VL>63</VL>
<NO>2</NO>
<PG>662-9</PG>
<IDENTIFIERS MODIFIED="2013-12-27 15:51:57 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 15:51:57 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12631132"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Assimos-2000" MODIFIED="2013-12-27 15:52:31 +1100" MODIFIED_BY="[Empty name]" NAME="Assimos 2000" TYPE="JOURNAL_ARTICLE">
<AU>Assimos DG, Holmes RP</AU>
<TI>Role of diet in the therapy of urolithiasis</TI>
<SO>Urologic Clinics of North America</SO>
<YR>2000</YR>
<VL>27</VL>
<NO>2</NO>
<PG>255-68</PG>
<IDENTIFIERS MODIFIED="2013-12-27 15:52:31 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 15:52:31 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="10778468"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bataille-1983" MODIFIED="2013-12-27 15:53:13 +1100" MODIFIED_BY="[Empty name]" NAME="Bataille 1983" TYPE="JOURNAL_ARTICLE">
<AU>Bataille P, Charransol G, Gregoire I, Daigre JL, Coevoet B, Makdassi R, et al</AU>
<TI>Effect of calcium restriction on renal excretion of oxalate and the probability of stones in the various pathophysiological groups with calcium stones</TI>
<SO>Journal of Urology</SO>
<YR>1983</YR>
<VL>130</VL>
<NO>2</NO>
<PG>218-23</PG>
<IDENTIFIERS MODIFIED="2013-12-27 15:53:13 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 15:53:13 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="6876264"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bihl-2001" MODIFIED="2013-12-27 15:53:45 +1100" MODIFIED_BY="[Empty name]" NAME="Bihl 2001" TYPE="JOURNAL_ARTICLE">
<AU>Bihl G, Meyers A</AU>
<TI>Recurrent renal stone disease-advances in pathogenesis and clinical management</TI>
<SO>Lancet</SO>
<YR>2001</YR>
<VL>358</VL>
<NO>9282</NO>
<PG>651-6</PG>
<IDENTIFIERS MODIFIED="2013-12-27 15:53:45 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 15:53:45 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11530173"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bourdeau-1994" MODIFIED="2013-12-27 15:54:09 +1100" MODIFIED_BY="[Empty name]" NAME="Bourdeau 1994" TYPE="BOOK_SECTION">
<AU>Bourdeau JE, Attie MF</AU>
<TI>Calcium metabolism</TI>
<SO>Maxwell and Kleemans clinical disorders of fluid and electrolyte metabolism</SO>
<YR>1994</YR>
<PG>243-306</PG>
<EN>5th</EN>
<ED>Narins NG</ED>
<PB>McGraw-Hill Inc. Health Professions Division</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Breslau-1982" MODIFIED="2013-12-27 15:55:01 +1100" MODIFIED_BY="[Empty name]" NAME="Breslau 1982" TYPE="JOURNAL_ARTICLE">
<AU>Breslau NA, McGuire JL, Zerwekh JE, Pak CY</AU>
<TI>The role of dietary sodium on renal excretion and intestinal absorption of calcium and on vitamin D metabolism</TI>
<SO>Journal of Clinical Endocrinology &amp; Metabolism</SO>
<YR>1982</YR>
<VL>55</VL>
<NO>2</NO>
<PG>369-73</PG>
<IDENTIFIERS MODIFIED="2013-12-27 15:55:01 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 15:55:01 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="6896338"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Breslau-1988" MODIFIED="2013-12-27 15:55:40 +1100" MODIFIED_BY="[Empty name]" NAME="Breslau 1988" TYPE="JOURNAL_ARTICLE">
<AU>Breslau NA, Brinkley L, Hill KD, Pak CY</AU>
<TI>Relationship of animal protein-rich diet to kidney stone formation and calcium metabolism</TI>
<SO>Journal of Clinical Endocrinology &amp; Metabolism</SO>
<YR>1988</YR>
<VL>66</VL>
<NO>1</NO>
<PG>140-6</PG>
<IDENTIFIERS MODIFIED="2013-12-27 15:55:40 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 15:55:40 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="2826524"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Caballero-2000" MODIFIED="2013-12-27 16:20:30 +1100" MODIFIED_BY="[Empty name]" NAME="Caballero 2000" TYPE="BOOK_SECTION">
<AU>Caballero CG</AU>
<TI>Idiopathic hypercalciuria</TI>
<SO>Nefrologia pediatrica</SO>
<YR>2000</YR>
<PG>475-83</PG>
<EN>1st</EN>
<ED>Garcia-Nieto V, Garcia-Perez J, Rodrigo D</ED>
<PB>Aula Medica Ediciones</PB>
<CY>Spain</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Coe-1982" MODIFIED="2013-12-27 15:58:35 +1100" MODIFIED_BY="[Empty name]" NAME="Coe 1982" TYPE="JOURNAL_ARTICLE">
<AU>Coe FL, Favus MJ, Crockett T, Strauss AL, Parks JH, Porat A, et al</AU>
<TI>Effects of low-calcium diet on urine calcium excretion, parathyroid function and serum 1,25(OH)2D3 levels in patients with idiopathic hypercalciuria and in normal subjects</TI>
<SO>American Journal of Medicine</SO>
<YR>1982</YR>
<VL>72</VL>
<NO>1</NO>
<PG>25-32</PG>
<IDENTIFIERS MODIFIED="2013-12-27 15:58:35 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 15:58:35 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="6277190"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Curhan-1993" MODIFIED="2013-12-27 16:00:07 +1100" MODIFIED_BY="[Empty name]" NAME="Curhan 1993" TYPE="JOURNAL_ARTICLE">
<AU>Curhan GC, Willett WC, Rimm EB, Stampfer MJ</AU>
<TI>A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones</TI>
<SO>New England Journal of Medicine</SO>
<YR>1993</YR>
<VL>328</VL>
<NO>12</NO>
<PG>833-8</PG>
<IDENTIFIERS MODIFIED="2013-12-27 16:00:07 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 16:00:07 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="8441427"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Curhan-1996" MODIFIED="2013-12-27 16:00:37 +1100" MODIFIED_BY="[Empty name]" NAME="Curhan 1996" TYPE="JOURNAL_ARTICLE">
<AU>Curhan GC, Willett WC, Rimm EB, Spiegelman D, Stampfer MJ</AU>
<TI>Prospective study of beverage use and the risk of kidney stones</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1996</YR>
<VL>143</VL>
<NO>3</NO>
<PG>240-7</PG>
<IDENTIFIERS MODIFIED="2013-12-27 16:00:37 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 16:00:37 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="8561157"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Curhan-1997a" MODIFIED="2013-12-27 16:02:21 +1100" MODIFIED_BY="[Empty name]" NAME="Curhan 1997a" TYPE="JOURNAL_ARTICLE">
<AU>Curhan GC, Willett WC, Speizer FE, Spiegelman D, Stampfer MJ</AU>
<TI>Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1997</YR>
<VL>126</VL>
<NO>7</NO>
<PG>497-504</PG>
<IDENTIFIERS MODIFIED="2013-12-27 16:02:21 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 16:02:21 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="9092314"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Curhan-1997b" MODIFIED="2013-12-27 16:03:34 +1100" MODIFIED_BY="[Empty name]" NAME="Curhan 1997b" TYPE="JOURNAL_ARTICLE">
<AU>Curhan GC</AU>
<TI>Dietary calcium, dietary protein, and kidney stone formation</TI>
<SO>Mineral &amp; Electrolyte Metabolism</SO>
<YR>1997</YR>
<VL>23</VL>
<NO>3-6</NO>
<PG>261-4</PG>
<IDENTIFIERS MODIFIED="2013-12-27 16:03:34 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 16:03:34 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="9387129"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Curhan-1998" MODIFIED="2013-12-27 16:03:54 +1100" MODIFIED_BY="[Empty name]" NAME="Curhan 1998" TYPE="JOURNAL_ARTICLE">
<AU>Curhan GC, Willett WC, Speizer FE, Stampfer MJ</AU>
<TI>Beverage use and risk for kidney stones in women</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1998</YR>
<VL>128</VL>
<NO>7</NO>
<PG>534-40</PG>
<IDENTIFIERS MODIFIED="2013-12-27 16:03:53 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 16:03:53 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="9518397"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Curhan-1999" MODIFIED="2013-12-27 16:04:31 +1100" MODIFIED_BY="[Empty name]" NAME="Curhan 1999" TYPE="JOURNAL_ARTICLE">
<AU>Curhan GC, Willett WC, Speizer FE, Stampfer MJ</AU>
<TI>Intake of vitamins B6 and C and the risk of kidney stones in women</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1999</YR>
<VL>10</VL>
<NO>4</NO>
<PG>840-5</PG>
<IDENTIFIERS MODIFIED="2013-12-27 16:04:29 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 16:04:29 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="10203369"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-de-Vernejoul-1983" MODIFIED="2013-12-27 16:07:30 +1100" MODIFIED_BY="[Empty name]" NAME="de Vernejoul 1983" TYPE="JOURNAL_ARTICLE">
<AU>de Vernejoul MC, Bielakoff J, Herve M, Gueris J, Hott M, Modrowski D, et al</AU>
<TI>Evidence for defective osteoblastic function. A role for alcohol and tobacco consumption in osteoporosis in middle-aged men</TI>
<SO>Clinical Orthopaedics &amp; Related Research</SO>
<YR>1983</YR>
<NO>179</NO>
<PG>107-15</PG>
<IDENTIFIERS MODIFIED="2013-12-27 16:07:25 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 16:07:25 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="6617002"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ebisuno-1986" MODIFIED="2013-12-27 16:08:19 +1100" MODIFIED_BY="[Empty name]" NAME="Ebisuno 1986" TYPE="JOURNAL_ARTICLE">
<AU>Ebisuno S, Morimoto S, Yoshida T, Fukatani T, Yasukawa S, Ohkawa T</AU>
<TI>Rice-bran treatment for calcium stone formers with idiopathic hypercalciuria</TI>
<SO>British Journal of Urology</SO>
<YR>1986</YR>
<VL>58</VL>
<NO>6</NO>
<PG>592-5</PG>
<IDENTIFIERS MODIFIED="2013-12-27 16:08:19 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 16:08:19 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="3801813"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Evan-2007" MODIFIED="2014-02-04 14:28:11 +1100" MODIFIED_BY="[Empty name]" NAME="Evan 2007" TYPE="JOURNAL_ARTICLE">
<AU>Evan AP, Coe FL, Lingeman JE, Shao Y, Sommer AJ, Bledsoe SB, et al</AU>
<TI>Mechanism of formation of human calcium oxalate renal stones on Randall's plaque</TI>
<SO>Anatomical Record (Hoboken, N.J. : 2007)</SO>
<YR>2007</YR>
<VL>290</VL>
<NO>10</NO>
<PG>1315-23</PG>
<IDENTIFIERS MODIFIED="2013-12-27 16:09:52 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 16:09:52 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17724713"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Frassetto-2007" MODIFIED="2014-02-04 14:30:33 +1100" MODIFIED_BY="[Empty name]" NAME="Frassetto 2007" TYPE="JOURNAL_ARTICLE">
<AU>Frassetto LA, Morris RC Jr, Sebastian A</AU>
<TI>Dietary sodium chloride intake independently predicts the degree of hyperchloremic metabolic acidosis in healthy humans consuming a net acid-producing diet</TI>
<SO>American Journal of Physiology - Renal Physiology</SO>
<YR>2007</YR>
<VL>293</VL>
<NO>2</NO>
<PG>F521-5</PG>
<IDENTIFIERS MODIFIED="2014-02-04 14:29:16 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-02-04 14:29:16 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="17522265"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Freundlich-2002" MODIFIED="2013-12-27 16:12:35 +1100" MODIFIED_BY="[Empty name]" NAME="Freundlich 2002" TYPE="JOURNAL_ARTICLE">
<AU>Freundlich M, Alonzo E, Bellorin-Font E, Weisinger JR</AU>
<TI>Reduced bone mass in children with idiopathic hypercalciuria and in their asymptomatic mothers</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>8</NO>
<PG>1396-401</PG>
<IDENTIFIERS MODIFIED="2013-12-27 16:12:35 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 16:12:35 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12147785"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fuss-1990" MODIFIED="2013-12-27 16:13:21 +1100" MODIFIED_BY="[Empty name]" NAME="Fuss 1990" TYPE="JOURNAL_ARTICLE">
<AU>Fuss M, Pepersack T, Bergman P, Hurard T, Simon J, Corvilain J</AU>
<TI>Low calcium diet in idiopathic urolithiasis: a risk factor for osteopenia as great as in primary hyperparathyroidism</TI>
<SO>British Journal of Urology</SO>
<YR>1990</YR>
<VL>65</VL>
<NO>6</NO>
<PG>560-3</PG>
<IDENTIFIERS MODIFIED="2013-12-27 16:13:21 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 16:13:21 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="2372668"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Garcia_x002d_Nieto-1997" MODIFIED="2013-12-27 16:14:48 +1100" MODIFIED_BY="[Empty name]" NAME="Garcia-Nieto 1997" TYPE="JOURNAL_ARTICLE">
<AU>Garcia-Nieto V, Ferrandez C, Monge M, de Sequera M, Rodrigo D</AU>
<TI>Bone mineral density in pediatric patients with idiopathic hypercalciuria</TI>
<SO>Pediatric Nephrology</SO>
<YR>1997</YR>
<VL>11</VL>
<NO>5</NO>
<PG>578-83</PG>
<IDENTIFIERS MODIFIED="2013-12-27 16:14:48 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 16:14:48 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="9323283"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Garcia_x002d_Sanchez-1995" MODIFIED="2013-12-27 16:22:07 +1100" MODIFIED_BY="[Empty name]" NAME="Garcia-Sanchez 1995" TYPE="JOURNAL_ARTICLE">
<AU>Garcia-Sanchez A, Gonzalez-Calvin JL, Diez-Ruiz A, Casals JL, Gallego-Rojo F, Salvatierra D</AU>
<TI>Effect of acute alcohol ingestion on mineral metabolism and osteoblastic function</TI>
<SO>Alcohol &amp; Alcoholism</SO>
<YR>1995</YR>
<VL>30</VL>
<NO>4</NO>
<PG>449-53</PG>
<IDENTIFIERS MODIFIED="2013-12-27 16:22:07 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 16:22:07 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="8540912"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ghazali-1974" MODIFIED="2014-01-06 22:58:09 +1100" MODIFIED_BY="[Empty name]" NAME="Ghazali 1974" TYPE="JOURNAL_ARTICLE">
<AU>Ghazali S, Barratt TM</AU>
<TI>Urinary excretion of calcium and magnesium in children</TI>
<SO>Arch Dis Child</SO>
<YR>1974</YR>
<VL>49</VL>
<PG>97-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gillen-2005" MODIFIED="2013-12-27 16:25:27 +1100" MODIFIED_BY="[Empty name]" NAME="Gillen 2005" TYPE="JOURNAL_ARTICLE">
<AU>Gillen DL, Worcester EM, Coe FL</AU>
<TI>Decreased renal function among adults with a history of nephrolithiasis: a study of NHANES III</TI>
<SO>Kidney International</SO>
<YR>2005</YR>
<VL>67</VL>
<NO>2</NO>
<PG>685-90</PG>
<IDENTIFIERS MODIFIED="2013-12-27 16:25:27 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 16:25:27 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15673317"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Harward-1993" MODIFIED="2013-12-27 16:26:04 +1100" MODIFIED_BY="[Empty name]" NAME="Harward 1993" TYPE="JOURNAL_ARTICLE">
<AU>Harward MP</AU>
<TI>Nutritive therapies for osteoporosis. The role of calcium</TI>
<SO>Medical Clinics of North America</SO>
<YR>1993</YR>
<VL>77</VL>
<NO>4</NO>
<PG>889-98</PG>
<IDENTIFIERS MODIFIED="2013-12-27 16:26:04 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 16:26:04 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="8321076"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Heilberg-2000" MODIFIED="2013-12-27 16:27:08 +1100" MODIFIED_BY="[Empty name]" NAME="Heilberg 2000" TYPE="JOURNAL_ARTICLE">
<AU>Heilberg IP</AU>
<TI>Update on dietary recommendations and medical treatment of renal stone disease</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>1</NO>
<PG>117-23</PG>
<IDENTIFIERS MODIFIED="2013-12-27 16:27:08 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 16:27:08 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="10607782"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2008-07-07 10:31:00 +1000" MODIFIED_BY="Narelle S Willis" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12958120"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2013-12-27 16:29:20 +1100" MODIFIED_BY="Narelle S Willis" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JP, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jahnen-1992" MODIFIED="2013-12-27 16:30:11 +1100" MODIFIED_BY="[Empty name]" NAME="Jahnen 1992" TYPE="JOURNAL_ARTICLE">
<AU>Jahnen A, Heynck H, Gertz B, Classen A, Hesse A</AU>
<TI>Dietary fibre: the effectiveness of a high bran intake in reducing renal calcium excretion</TI>
<SO>Urological Research</SO>
<YR>1992</YR>
<VL>20</VL>
<NO>1</NO>
<PG>3-6</PG>
<IDENTIFIERS MODIFIED="2013-12-27 16:30:11 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 16:30:11 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="1310550"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kuo-2003" MODIFIED="2013-12-27 16:30:50 +1100" MODIFIED_BY="[Empty name]" NAME="Kuo 2003" TYPE="JOURNAL_ARTICLE">
<AU>Kuo RL, Lingeman JE, Evan AP, Paterson RF, Parks JH, Bledsoe SB, et al</AU>
<TI>Urine calcium and volume predict coverage of renal papilla by Randalls plaque</TI>
<SO>Kidney International</SO>
<YR>2003</YR>
<VL>64</VL>
<NO>6</NO>
<PG>2150-4</PG>
<IDENTIFIERS MODIFIED="2013-12-27 16:30:50 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 16:30:50 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="14633137"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Langman-1984" MODIFIED="2013-12-27 16:31:29 +1100" MODIFIED_BY="[Empty name]" NAME="Langman 1984" TYPE="JOURNAL_ARTICLE">
<AU>Langman CB, Moore ES</AU>
<TI>Hypercalciuria in clinical pediatrics</TI>
<SO>Clinical Pediatrics</SO>
<YR>1984</YR>
<VL>23</VL>
<NO>3</NO>
<PG>135-7</PG>
<IDENTIFIERS MODIFIED="2013-12-27 16:31:29 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 16:31:29 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="6365401"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lemann-1996" MODIFIED="2013-12-27 16:32:05 +1100" MODIFIED_BY="[Empty name]" NAME="Lemann 1996" TYPE="JOURNAL_ARTICLE">
<AU>Lemann J Jr, Pleuss JA, Worcester EM, Hornick L, Schrab D, Hoffmann RG</AU>
<TI>Urinary oxalate excretion increases with body size and decreases with increasing dietary calcium intake among healthy adults</TI>
<SO>Kidney International</SO>
<YR>1996</YR>
<VL>49</VL>
<NO>1</NO>
<PG>200-8</PG>
<IDENTIFIERS MODIFIED="2013-12-27 16:32:05 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 16:32:05 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="8770968"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lerolle-2002" MODIFIED="2013-12-27 16:33:00 +1100" MODIFIED_BY="[Empty name]" NAME="Lerolle 2002" TYPE="JOURNAL_ARTICLE">
<AU>Lerolle N, Lantz B, Paillard F, Gattegno B, Flahault A, Ronco P, et al</AU>
<TI>Risk factors for nephrolithiasis in patients with familial idiopathic hypercalciuria</TI>
<SO>American Journal of Medicine</SO>
<YR>2002</YR>
<VL>113</VL>
<NO>2</NO>
<PG>99-103</PG>
<IDENTIFIERS MODIFIED="2013-12-27 16:33:00 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 16:33:00 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12133747"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leslie-2000" MODIFIED="2011-02-23 11:38:18 +1100" MODIFIED_BY="[Empty name]" NAME="Leslie 2000" TYPE="BOOK_SECTION">
<AU>Leslie S, Savitz G</AU>
<TI>Calcium and stone disease</TI>
<SO>The kidney stones handbook. A patient's guide to hope, cure and prevention</SO>
<YR>2000</YR>
<VL>1</VL>
<PG>99-103</PG>
<EN>2nd</EN>
<PB>Four Geez Press</PB>
<CY>Roseville (USA)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liatsikos-1999" MODIFIED="2013-12-27 16:33:53 +1100" MODIFIED_BY="[Empty name]" NAME="Liatsikos 1999" TYPE="JOURNAL_ARTICLE">
<AU>Liatsikos FN, Barbalias GA</AU>
<TI>The influence of a low protein diet in idiopathic hypercalciuria</TI>
<SO>International Urology &amp; Nephrology</SO>
<YR>1999</YR>
<VL>31</VL>
<NO>3</NO>
<PG>271-6</PG>
<IDENTIFIERS MODIFIED="2013-12-27 16:33:53 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 16:33:53 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="10672943"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Martini-2000" MODIFIED="2013-12-27 16:34:36 +1100" MODIFIED_BY="[Empty name]" NAME="Martini 2000" TYPE="JOURNAL_ARTICLE">
<AU>Martini LA, Cuppari L, Colugnati FA, Sigulem DM, Szejnfeld VL, Schor N, et al</AU>
<TI>High sodium chloride intake is associated with low bone density in calcium stone-forming patients</TI>
<SO>Clinical Nephrology</SO>
<YR>2000</YR>
<VL>54</VL>
<NO>2</NO>
<PG>85-93</PG>
<IDENTIFIERS MODIFIED="2013-12-27 16:34:36 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 16:34:36 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="10968683"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-McHarg-2003" MODIFIED="2013-12-27 16:37:50 +1100" MODIFIED_BY="[Empty name]" NAME="McHarg 2003" TYPE="JOURNAL_ARTICLE">
<AU>McHarg T, Rodgers A, Charlton K</AU>
<TI>Influence of cranberry juice on the urinary risk factors for calcium oxalate kidney stone formation</TI>
<SO>BJU International</SO>
<YR>2003</YR>
<VL>92</VL>
<NO>7</NO>
<PG>765-8</PG>
<IDENTIFIERS MODIFIED="2013-12-27 16:37:50 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 16:37:50 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="14616463"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moe-2006" MODIFIED="2013-12-27 16:38:39 +1100" MODIFIED_BY="[Empty name]" NAME="Moe 2006" TYPE="JOURNAL_ARTICLE">
<AU>Moe OW</AU>
<TI>Kidney stones: pathophysiology and medical management</TI>
<SO>Lancet</SO>
<YR>2006</YR>
<VL>367</VL>
<NO>9507</NO>
<PG>333-44</PG>
<IDENTIFIERS MODIFIED="2013-12-27 16:38:39 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 16:38:39 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16443041"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Morgan-1994" MODIFIED="2013-12-27 16:41:21 +1100" MODIFIED_BY="[Empty name]" NAME="Morgan 1994" TYPE="JOURNAL_ARTICLE">
<AU>Morgan LJ, Liebman M, Broughton KS</AU>
<TI>Caffeine-induced hypercalciuria and renal prostaglandins: effect of aspirin and n-3 polyunsaturated fatty acids</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1994</YR>
<VL>60</VL>
<NO>3</NO>
<PG>362-8</PG>
<IDENTIFIERS MODIFIED="2013-12-27 16:41:21 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 16:41:21 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="8074066"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Muldowney-1982" MODIFIED="2013-12-27 16:41:56 +1100" MODIFIED_BY="[Empty name]" NAME="Muldowney 1982" TYPE="JOURNAL_ARTICLE">
<AU>Muldowney FP, Freaney R, Moloney MF</AU>
<TI>Importance of dietary sodium in the hypercalciuria syndrome</TI>
<SO>Kidney International</SO>
<YR>1982</YR>
<VL>22</VL>
<NO>3</NO>
<PG>292-6</PG>
<IDENTIFIERS MODIFIED="2013-12-27 16:41:56 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 16:41:56 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="7176331"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pak-2003" MODIFIED="2013-12-27 16:57:47 +1100" MODIFIED_BY="[Empty name]" NAME="Pak 2003" TYPE="JOURNAL_ARTICLE">
<AU>Pak CY, Heller HJ, Pearle MS, Odvina CV, Poindexter JR, Peterson RD</AU>
<TI>Prevention of stone formation and bone loss in absorptive hypercalciuria by combined dietary and pharmacological interventions</TI>
<SO>Journal of Urolology</SO>
<YR>2003</YR>
<VL>169</VL>
<NO>2</NO>
<PG>465-9</PG>
<IDENTIFIERS MODIFIED="2013-12-27 16:57:47 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 16:57:47 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12544288"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pak-2005" MODIFIED="2013-12-27 16:58:21 +1100" MODIFIED_BY="Narelle S Willis" NAME="Pak 2005" TYPE="JOURNAL_ARTICLE">
<AU>Pak CY, Odvina CV, Pearle MS, Sakhaee K, Peterson RD, Poindexter JR, et al</AU>
<TI>Effect of dietary modification on urinary stone risk factors</TI>
<SO>Kidney International</SO>
<YR>2005</YR>
<VL>5</VL>
<NO>68</NO>
<PG>2264-73</PG>
<IDENTIFIERS MODIFIED="2013-12-27 16:58:21 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 16:58:21 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16221228"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Premgamone-2001" MODIFIED="2013-12-27 16:58:59 +1100" MODIFIED_BY="[Empty name]" NAME="Premgamone 2001" TYPE="JOURNAL_ARTICLE">
<AU>Premgamone A, Sriboonblue P, Disatapornjaroen W, Maskasem S, Sinsupan N, Apinives C</AU>
<TI>A long-term study on the efficacy of a herbal plant, Orthosiphon grandiflorus, and sodium potassium citrate in renal calculi treatment</TI>
<SO>Southeast Asian Journal of Tropical Medicine &amp; Public Health</SO>
<YR>2001</YR>
<VL>32</VL>
<NO>3</NO>
<PG>654-60</PG>
<IDENTIFIERS MODIFIED="2013-12-27 16:58:59 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 16:58:59 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11944733"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Prie-2001" MODIFIED="2013-12-27 16:59:38 +1100" MODIFIED_BY="[Empty name]" NAME="Prie 2001" TYPE="JOURNAL_ARTICLE">
<AU>Prie D, Ravery D, Boccon-Gibod L, Friedlander G</AU>
<TI>Frequency of renal phosphate leak among patients with calcium nephrolithiasis</TI>
<SO>Kidney International</SO>
<YR>2001</YR>
<VL>60</VL>
<NO>1</NO>
<PG>272-6</PG>
<IDENTIFIERS MODIFIED="2013-12-27 16:59:38 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 16:59:38 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11422761"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Qiang-2004" MODIFIED="2008-08-04 16:53:57 +1000" MODIFIED_BY="Narelle S Willis" NAME="Qiang 2004" TYPE="COCHRANE_REVIEW">
<AU>Qiang W, Ke Z</AU>
<TI>Water for preventing urinary calculi</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-08-04 16:53:57 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-08-04 16:53:57 +1000" MODIFIED_BY="Narelle S Willis" TYPE="DOI" VALUE="10.1002/14651858.CD004292.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rodgers-2002" MODIFIED="2013-12-27 17:00:33 +1100" MODIFIED_BY="[Empty name]" NAME="Rodgers 2002" TYPE="JOURNAL_ARTICLE">
<AU>Rodgers AL, Lewandowski S</AU>
<TI>Effects of 5 different diets on urinary risk factors for calcium oxalate kidney stone formation: evidence of different renal handling mechanisms in different race groups</TI>
<SO>Journal of Urology</SO>
<YR>2002</YR>
<VL>168</VL>
<NO>3</NO>
<PG>931-6</PG>
<IDENTIFIERS MODIFIED="2013-12-27 17:00:33 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 17:00:33 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12187193"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sakhaee-1993" MODIFIED="2013-12-27 17:01:21 +1100" MODIFIED_BY="[Empty name]" NAME="Sakhaee 1993" TYPE="JOURNAL_ARTICLE">
<AU>Sakhaee K, Harvey JA, Padalino PK, Whitson P, Pak CY</AU>
<TI>The potential role of salt abuse on the risk for kidney stone formation</TI>
<SO>Journal of Urology</SO>
<YR>1993</YR>
<VL>150</VL>
<NO>2 Pt 1</NO>
<PG>310-2</PG>
<IDENTIFIERS MODIFIED="2013-12-27 17:01:21 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 17:01:21 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="8326549"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sakhaee-2011" MODIFIED="2013-12-27 17:02:00 +1100" MODIFIED_BY="[Empty name]" NAME="Sakhaee 2011" TYPE="JOURNAL_ARTICLE">
<AU>Sakhaee K, Maalouf NM, Kumar R, Pasch A, Moe OW</AU>
<TI>Nephrolithiasis-associated bone disease: pathogenesis and treatment options</TI>
<SO>Kidney International</SO>
<YR>2011</YR>
<VL>79</VL>
<NO>4</NO>
<PG>393-403</PG>
<IDENTIFIERS MODIFIED="2013-12-27 17:02:00 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 17:02:00 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="21124301"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Shuster-1992" MODIFIED="2013-12-27 17:02:45 +1100" MODIFIED_BY="[Empty name]" NAME="Shuster 1992" TYPE="JOURNAL_ARTICLE">
<AU>Shuster J, Jenkins A, Logan C, Barnett T, Riehle R, Zackson D, et al</AU>
<TI>Soft drink consumption and urinary stone recurrence: a randomized prevention trial</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1992</YR>
<VL>45</VL>
<NO>8</NO>
<PG>911-6</PG>
<IDENTIFIERS MODIFIED="2013-12-27 17:02:45 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 17:02:45 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="1624973"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Siener-2005" MODIFIED="2013-12-27 17:03:14 +1100" MODIFIED_BY="[Empty name]" NAME="Siener 2005" TYPE="JOURNAL_ARTICLE">
<AU>Siener R, Schade N, Nicolay C, von Unruh GE, Hesse A</AU>
<TI>The efficacy of dietary intervention on urinary risk factors for stone formation in recurrent calcium oxalate stone patients</TI>
<SO>Journal of Urology</SO>
<YR>2005</YR>
<VL>173</VL>
<NO>5</NO>
<PG>1601-5</PG>
<IDENTIFIERS MODIFIED="2013-12-27 17:03:14 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 17:03:14 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15821507"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Stapleton-1987" MODIFIED="2013-12-27 17:04:13 +1100" MODIFIED_BY="[Empty name]" NAME="Stapleton 1987" TYPE="JOURNAL_ARTICLE">
<AU>Stapleton FB, McKay CP, Noe HN</AU>
<TI>Urolithiasis in children: the role of hypercalciuria</TI>
<SO>Pediatric Annals</SO>
<YR>1987</YR>
<VL>16</VL>
<NO>12</NO>
<PG>980-1, 984-92</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3320916"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tiselius-2000" MODIFIED="2013-12-27 17:06:43 +1100" MODIFIED_BY="[Empty name]" NAME="Tiselius 2000" TYPE="JOURNAL_ARTICLE">
<AU>Tiselius HG</AU>
<TI>Metabolic evaluation and therapy</TI>
<SO>Current Opinion in Urology</SO>
<YR>2000</YR>
<VL>10</VL>
<NO>6</NO>
<PG>545-9</PG>
<IDENTIFIERS MODIFIED="2013-12-27 17:06:43 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 17:06:43 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11148723"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vachvanichsanong-2001" MODIFIED="2013-12-27 17:08:13 +1100" MODIFIED_BY="[Empty name]" NAME="Vachvanichsanong 2001" TYPE="JOURNAL_ARTICLE">
<AU>Vachvanichsanong P, Malagon M, Moore ES</AU>
<TI>Urinary tract infection in children associated with idiopathic hypercalciuria</TI>
<SO>Scandinavian Journal of Urology &amp; Nephrology</SO>
<YR>2001</YR>
<VL>35</VL>
<NO>2</NO>
<PG>112-6</PG>
<IDENTIFIERS MODIFIED="2013-12-27 17:08:09 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 17:08:09 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11411652"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Williams-1996" MODIFIED="2013-12-27 17:09:22 +1100" MODIFIED_BY="[Empty name]" NAME="Williams 1996" TYPE="JOURNAL_ARTICLE">
<AU>Williams CP, Child DF, Hudson PR, De Soysa L, Davies GK, Davies MG, et al</AU>
<TI>Inappropriate phosphate excretion in idiopathic hypercalciuria: the key to a common cause and future treatment?</TI>
<SO>Journal of Clinical Pathology</SO>
<YR>1996</YR>
<VL>49</VL>
<NO>11</NO>
<PG>881-8</PG>
<IDENTIFIERS MODIFIED="2013-12-27 17:09:03 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 17:09:03 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="8944605"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Worcester-2007" MODIFIED="2013-12-27 17:11:14 +1100" MODIFIED_BY="[Empty name]" NAME="Worcester 2007" TYPE="JOURNAL_ARTICLE">
<AU>Worcester E, Gillen DL, Evan AP, Parks JH, Wright K, Trumbore L, et al</AU>
<TI>Evidence that postprandial reduction of renal calcium reabsorption mediates hypercalciuria of patients with calcium nephrolithiasis</TI>
<SO>American Journal of Physiology - Renal Physiology</SO>
<YR>2007</YR>
<VL>292</VL>
<NO>1</NO>
<PG>F66-75</PG>
<IDENTIFIERS MODIFIED="2013-12-27 17:11:14 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-27 17:11:14 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17210796"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2014-02-06 08:12:05 +1100" MODIFIED_BY="Narelle S Willis">
<REFERENCE ID="REF-Balaguer-2008" MODIFIED="2014-02-06 08:12:05 +1100" MODIFIED_BY="Narelle S Willis" NAME="Balaguer 2008" TYPE="COCHRANE_PROTOCOL">
<AU>Balaguer A, Escribano J, Feliu A, Roqué i Figuls M</AU>
<TI>Dietary interventions for preventing complications in idiopathic hypercalciuria</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2014-02-06 08:12:00 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-02-06 08:12:00 +1100" MODIFIED_BY="Narelle S Willis" TYPE="DOI" VALUE="10.1002/14651858.CD006022.pub3"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-02-04 18:30:39 +1100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-02-04 18:30:39 +1100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-12-30 16:01:40 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Borghi-2002">
<CHAR_METHODS MODIFIED="2013-12-30 12:47:37 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: June 1993 to December 1994</LI>
<LI>Study duration: 5 years</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-30 16:01:40 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Setting: single centre</LI>
<LI>Country: Italy</LI>
<LI>Men with idiopathic hypercalciuria (urinary calcium excretion, &gt; 300 mg/d (7.5 mmol/d) on an unrestricted diet, recurrent formation of calcium oxalate stones (at least two documented events (colic episodes with expulsion of stones or radiographic evidence of retained stones)), no previous visit to a stone disease centre, no current treatment for the prevention of recurrent stones except for the advice to increase water intake</LI>
<LI>Number: treatment group 1 (60); treatment group 2 (60)</LI>
<LI>Mean age ± SD (years): treatment group 1 (45.4 ± 10.9); treatment group 2 (44.8 ± 9.2)</LI>
<LI>Sex (M/F): all male</LI>
<LI>Exclusion criteria: primary hyperparathyroidism, primary hyperoxaluria, enteric hyperoxaluria, bowel resection, inflammatory bowel disease, renal tubular acidosis, sarcoidosis, or sponge kidney</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-30 16:01:16 +1100" MODIFIED_BY="[Empty name]">
<P>Treatment group 1</P>
<UL>
<LI>Low calcium diet: 10 mmol/d</LI>
<LI>Water intake: 2 to 3 L/d</LI>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>Normal-to-high intake of calcium: 30 mmol/d</LI>
<LI>Low protein diet: &lt; 15% of total energy</LI>
<LI>Low salt diet: &lt; 50 mmol/d</LI>
<LI>Water intake: 2 to 3 L/d</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-30 12:50:18 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Stone formation: time to first symptomatic or radiographically identified stone</LI>
<LI>Changes in calcium and oxalate excretion, calcium oxalate product, and relative calcium oxalate saturation</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-07-11 23:56:56 +1000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-04 13:48:32 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Coe-1992">
<CHAR_METHODS MODIFIED="2013-12-30 16:03:43 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: cross-over RCT. Two treatment phases 28 days in length (periods I and 2), 2, 7-day baseline periods and a 7-day washout period at the start of the study and again between treatments</LI>
<LI>Time frame: NS</LI>
<LI>Study duration: 76 days</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-30 16:09:09 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Setting: single centre</LI>
<LI>Country: USA</LI>
<LI>Healthy, relatives of hypercalciuric stone-forming patients, without any clinical manifestation</LI>
<LI>Number: 12</LI>
<LI>Age 18 to 30 years</LI>
<LI>Sex (M/F): 6/6</LI>
<LI>Exclusion criteria: NS</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-04 13:48:32 +1100" MODIFIED_BY="[Empty name]">
<P>Treatment group 1</P>
<UL>
<LI>2% milk: 2 x 8 oz glasses/d</LI>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>Orange juice + calcium citrate malate salt supplement: 2 x 6 oz glasses/d (calcium supplement: 600 mg/d)</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-30 16:08:49 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Reduction in 24 h urine calciuria and oxaluria</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-04 13:48:47 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gleeson-1990">
<CHAR_METHODS MODIFIED="2013-12-30 16:16:57 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Study duration: 3 weeks</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-30 16:16:25 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Setting: single centre</LI>
<LI>Country: USA</LI>
<LI>Patients with a previous history of renal calculus formation and know hypercalciuria (&gt; 200 mg/d)</LI>
<LI>Number: treatment group (9); control group (8)</LI>
<LI>Age range: 39 to 65 years</LI>
<LI>Sex (M/F): 16/1</LI>
<LI>Exclusion criteria: NS</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-04 13:48:47 +1100" MODIFIED_BY="[Empty name]">
<P>Treatment group<BR/>
</P>
<UL>
<LI>Calcium (301 mg) and oxalate (202 mg) diet</LI>
<LI>Unprocessed wheat bran: 78.2 g</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Calcium (370 mg) and oxalate (38 mg) diet</LI>
</UL>
<P>Pharmacological co-intervention with hydrochlorothiazide (50 µg/12 h) + potassium citrate (5 mEq/8 h) in both groups</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-30 16:21:17 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Reduction in 24 h urine calciuria and oxaluria</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-30 16:21:51 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Drop-outs: NS</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-04 18:30:12 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nishiura-2004">
<CHAR_METHODS MODIFIED="2013-12-30 16:28:09 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Study duration: 3 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-04 18:30:12 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Setting: Single centre</LI>
<LI>Country: Brazil</LI>
<LI>Patients with at least one kidney stone</LI>
<LI>Number: treatment group (33); control group (36)</LI>
<LI>Mean age ± SD (years): treatment group (39 ± 9); control group (37 ± 8)</LI>
<LI>Sex (M/F): treatment group (17/16); control group (22/14)</LI>
<LI>Exclusion criteria: patients with diseases that might have led to secondary calcium stones, such as primary hyperparathyroidism, distal renal tubular acidosis, UTIs, primary hyperoxaluria</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-04 14:37:41 +1100" MODIFIED_BY="[Empty name]">
<P>Treatment group</P>
<UL>
<LI>
<I>Phyllanthus niruri </I>capsules:<I> </I>450 mg, 3 times/d</LI>
</UL>
<P>Control group</P>
<UL>
<LI>
<I>Chicorium sativum </I>capsules:<I> </I>450 mg, 3 times/d</LI>
</UL>
<P>Co-interventions: NS</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-30 16:31:11 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Reduction in calciuria (24 h urine calciuria or calcium/creatinine ratio)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-01-29 10:01:23 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Dropouts: NS</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-04 13:45:15 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nouvenne-2010">
<CHAR_METHODS MODIFIED="2013-12-30 16:41:38 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: parallel RCT, stratified according to sex</LI>
<LI>Time frame: January 2005 to December 2007</LI>
<LI>Study duration: 3 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-04 13:45:15 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Setting:</LI>
<LI>Country: Italy</LI>
<LI>Patients with hypercalciuria, with at least one oxalate calcium stone excretion episode</LI>
<LI>Number: treatment group (108); control group (102)</LI>
<LI>Mean age ± SD (years): treatment group (39 ± 9); control group (40 ± 10)</LI>
<LI>Sex (M/F): treatment group (78/30); control group (72/30)</LI>
<LI>Exclusion criteria: primary hyperparathyroidism, primary hyperoxaluria, enteric hyperoxaluria, bowel resection, inflammatory bowel disease, renal tubular acidosis, sarcoidosis, sponge kidney, and hyperthyroidism; chronic use of drugs capable of increasing the risk of calcium stone formation, such as vitamin D, acetazolamide, and antiepileptic drugs</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-30 16:44:13 +1100" MODIFIED_BY="[Empty name]">
<P>Treatment group</P>
<UL>
<LI>Low salt diet: no salt used in cooking or added to foods</LI>
<LI>Water: 2 to 3 L/d</LI>
<LI>Calcium: normal levels (800 to 100 mg/d)</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Water: 2 to 3 L/d</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-30 16:44:23 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Reduction in 24 h urine calciuria and oxaluria</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-07-12 00:25:45 +1000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>NS - not stated; UTI - urinary tract infection</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-01-06 23:14:32 +1100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-01-03 04:47:00 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ala_x002d_Opas-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-02 05:07:48 +1100" MODIFIED_BY="[Empty name]">
<P>Wrong intervention: patients treated with thiazides</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-03 04:47:05 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aras-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-02 05:08:04 +1100" MODIFIED_BY="[Empty name]">
<P>Wrong population: study performed in patients with hypocitraturia</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-03 04:47:10 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baxmann-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-02 05:08:20 +1100" MODIFIED_BY="[Empty name]">
<P>Wrong population: no patients with hypercalciuria included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-03 04:47:15 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bellizzi-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-02 05:08:34 +1100" MODIFIED_BY="[Empty name]">
<P>Wrong population: no patients with hypercalciuria included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-21 17:21:56 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Borghi-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-21 17:21:56 +1100" MODIFIED_BY="[Empty name]">
<P>No data analysis of hypercalciuria group participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-21 17:22:08 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Campoy-Martinez-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-21 17:22:08 +1100" MODIFIED_BY="[Empty name]">
<P>No data analysis of hypercalciuria group participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-12 16:07:24 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Colette-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-12 16:07:24 +1100" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-03 04:47:22 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Domrongkitchaiporn-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-02 05:08:56 +1100" MODIFIED_BY="[Empty name]">
<P>Wrong population: no patients with hypercalciuria included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-21 17:23:21 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hiatt-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-21 17:23:21 +1100" MODIFIED_BY="[Empty name]">
<P>No data analysis of hypercalciuria group participants. Patients had histories of recurrent calcium oxalate kidney stones. RCT evaluated effects of low animal protein/high fibre diet plus fluid and calcium intake recommendations versus fluid and calcium intake recommendations alone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-21 16:28:09 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jaeger-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-21 16:28:09 +1100" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-06 23:14:32 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Karagulle-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-06 23:14:13 +1100" MODIFIED_BY="[Empty name]">
<P>No data analysis of hypercalciuria group participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-21 17:23:56 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kocvara-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-21 17:23:56 +1100" MODIFIED_BY="[Empty name]">
<P>No data analysis of hypercalciuria group participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-03 04:47:35 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lamid-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-02 05:10:07 +1100" MODIFIED_BY="[Empty name]">
<P>Wrong population: study performed in spinal cord injury patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-03 04:47:38 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Matsumoto-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-02 05:10:24 +1100" MODIFIED_BY="[Empty name]">
<P>Wrong population: no patients with hypercalciuria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-21 16:28:47 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Muller-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-21 16:28:47 +1100" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-21 17:24:19 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rotily-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-21 17:24:19 +1100" MODIFIED_BY="[Empty name]">
<P>No data analysis of hypercalciuria group participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-12 16:08:02 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schwille-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-12 16:08:02 +1100" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-27 12:35:52 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-van-Faassen-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-27 12:35:52 +1100" MODIFIED_BY="[Empty name]">
<P>Data not provided on each group at the end of the intervention; intra-group differences reported from baseline only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2013-04-23 15:00:02 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-02-04 13:48:57 +1100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-03-21 17:17:44 +1100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-21 16:55:20 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Borghi-2002">
<DESCRIPTION>
<P>Randomisation generated by an investigator. Random number sequence (odd number group A and even number group B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-12 16:01:42 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Coe-1992">
<DESCRIPTION>
<P>Randomisation method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-12 16:03:42 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gleeson-1990">
<DESCRIPTION>
<P>Randomisation method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-12 16:04:56 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nishiura-2004">
<DESCRIPTION>
<P>Randomisation method unspecified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-21 17:17:44 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nouvenne-2010">
<DESCRIPTION>
<P>Computer-generated 2 sequences of random treatment assignments. Randomisation was stratified according to sex</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-03-21 17:17:55 +1100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-21 16:55:37 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Borghi-2002">
<DESCRIPTION>
<P>Random number sequence enclosed in sealed, numbered envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-12 16:01:50 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Coe-1992">
<DESCRIPTION>
<P>Allocation concealment not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-12 16:03:45 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gleeson-1990">
<DESCRIPTION>
<P>Allocation method unspecified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-12 16:04:59 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nishiura-2004">
<DESCRIPTION>
<P>Allocation method unspecified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-21 17:17:55 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nouvenne-2010">
<DESCRIPTION>
<P>Treatment assignment was concealed from the doctor and the patient by using 2 series of sealed, progressively numbered envelopes for men and women</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2013-03-12 16:06:56 +1100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-03-12 16:01:03 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Borghi-2002">
<DESCRIPTION>
<P>Due to the nature of the intervention, patients and researchers were not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-03-12 16:01:55 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Coe-1992">
<DESCRIPTION>
<P>No blinding of intervention and outcome measurement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-03-12 16:03:48 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gleeson-1990">
<DESCRIPTION>
<P>Due to the nature of the intervention, patients and researchers were not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-03-12 16:05:16 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nishiura-2004">
<DESCRIPTION>
<P>
<I>P. niruri</I> and placebo capsules were manufactured in the same way</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-03-12 16:06:56 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nouvenne-2010">
<DESCRIPTION>
<P>Due to the nature of the intervention, patients and researchers were not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-02-04 13:48:14 +1100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-04 13:48:14 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Borghi-2002">
<DESCRIPTION>
<P>Drop-outs reported: 17 did not complete the study: 9 patients in Group A (hypertension (7) died (2)); 8 in Group B (hypertension (1), gout (1), embolism (1), lost to follow-up (2), withdrew consent (3))</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-21 17:07:55 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Coe-1992">
<DESCRIPTION>
<P>Drop-outs not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-21 17:07:04 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gleeson-1990">
<DESCRIPTION>
<P>Drop-outs not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-29 10:00:43 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nishiura-2004">
<DESCRIPTION>
<P>Dropouts not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-21 17:20:38 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nouvenne-2010">
<DESCRIPTION>
<P>13 participants did not complete the study: 2 patients in Group A (due to work problems to assist visits) and 11 patients in Group B (due to adaptation problems to low salt diet)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-03-21 17:20:24 +1100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-12 16:01:05 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Borghi-2002">
<DESCRIPTION>
<P>Free of suggestion of selective outcome reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-21 17:02:30 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coe-1992">
<DESCRIPTION>
<P>Apparently free of selective outcome reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-21 17:07:29 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gleeson-1990">
<DESCRIPTION>
<P>Apparently free of selective outcome reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-21 17:11:28 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nishiura-2004">
<DESCRIPTION>
<P>Apparently free of selective outcome reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-21 17:20:24 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nouvenne-2010">
<DESCRIPTION>
<P>Apparently free of selective outcome reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2014-02-04 13:48:57 +1100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-12 16:00:58 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Borghi-2002">
<DESCRIPTION>
<P>Apparently free of other problems that could put it at a risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-21 17:02:10 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coe-1992">
<DESCRIPTION>
<P>Apparently free of other factors that could influence bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-04 13:48:57 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gleeson-1990">
<DESCRIPTION>
<P>Pharmacological co-intervention with hydrochlorothiazide (50 µg/12 h) + potassium citrate (5 mEq/8 h) in both groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-21 16:45:32 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nishiura-2004">
<DESCRIPTION>
<P>Possible differences in co-intervention between groups not excluded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-21 17:20:06 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nouvenne-2010">
<DESCRIPTION>
<P>Study findings applicable only to patients used to high salt diets (averaging up to 13 g/d)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-02-06 08:08:29 +1100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2014-02-06 08:08:29 +1100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Low calcium diet versus normal calcium, low protein, low salt diet</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="37" EVENTS_2="48" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-01-06 23:22:53 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="60" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>No new recurrences of kidney stones</NAME>
<GROUP_LABEL_1>Low calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Normal calcium</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours normal calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours low calcium</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9762346225531309" CI_START="0.6086487961508862" EFFECT_SIZE="0.7708333333333334" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="48" LOG_CI_END="-0.01044579397806827" LOG_CI_START="-0.2156332326391161" LOG_EFFECT_SIZE="-0.1130395133085922" MODIFIED="2014-01-06 23:22:53 +1100" MODIFIED_BY="[Empty name]" ORDER="21" O_E="0.0" SE="0.12052811716370178" STUDY_ID="STD-Borghi-2002" TOTAL_1="60" TOTAL_2="60" VAR="0.014527027027027024" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2014-01-06 23:25:57 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="28" TOTAL_2="40" UNITS="mmol/d" WEIGHT="0.0" Z="0.0">
<NAME>Urinary calcium levels</NAME>
<GROUP_LABEL_1>Low calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Normal calcium</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours normal calcium</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.1664472341290826" CI_START="-0.566447234129083" EFFECT_SIZE="0.2999999999999998" ESTIMABLE="YES" MEAN_1="6.2" MEAN_2="5.9" MODIFIED="2014-01-06 23:25:57 +1100" MODIFIED_BY="[Empty name]" ORDER="24" SD_1="1.2" SD_2="2.4" SE="0.44207303856780433" STUDY_ID="STD-Borghi-2002" TOTAL_1="28" TOTAL_2="40" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2014-01-06 23:26:57 +1100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="28" TOTAL_2="40" UNITS="µmol/d" WEIGHT="0.0" Z="0.0">
<NAME>Urinary oxalate levels</NAME>
<GROUP_LABEL_1>Low calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Normal calcium</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours normal calcium</GRAPH_LABEL_2>
<CONT_DATA CI_END="129.52106953575463" CI_START="26.47893046424536" EFFECT_SIZE="78.0" ESTIMABLE="YES" MEAN_1="411.0" MEAN_2="333.0" MODIFIED="2014-01-06 23:26:57 +1100" MODIFIED_BY="[Empty name]" ORDER="25" SD_1="121.0" SD_2="82.0" SE="26.286742992292847" STUDY_ID="STD-Borghi-2002" TOTAL_1="28" TOTAL_2="40" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2014-01-06 23:28:23 +1100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="28" TOTAL_2="40" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Calcium oxalate relative supersaturation index</NAME>
<GROUP_LABEL_1>Low calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Normal calcium</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours normal calcium</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.187512916687565" CI_START="0.2124870833124357" EFFECT_SIZE="1.2000000000000002" ESTIMABLE="YES" MEAN_1="4.7" MEAN_2="3.5" MODIFIED="2014-01-06 23:28:23 +1100" MODIFIED_BY="[Empty name]" ORDER="26" SD_1="2.2" SD_2="1.8" SE="0.50384237898091" STUDY_ID="STD-Borghi-2002" TOTAL_1="28" TOTAL_2="40" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-01-06 23:29:03 +1100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="60" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>Changes in blood pressure</NAME>
<GROUP_LABEL_1>Low calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Normal calcium</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours normal calcium</GRAPH_LABEL_2>
<DICH_DATA CI_END="55.1698914760233" CI_START="0.8881656042643342" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.7417021296635475" LOG_CI_START="-0.051506049635034135" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2014-01-06 23:29:03 +1100" MODIFIED_BY="[Empty name]" ORDER="27" O_E="0.0" SE="1.0533393610436332" STUDY_ID="STD-Borghi-2002" TOTAL_1="60" TOTAL_2="60" VAR="1.1095238095238096" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2014-01-30 18:22:18 +1100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Low salt, normal calcium diet versus normal salt diet</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2013-08-12 18:22:04 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="108" TOTAL_2="102" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Urinary calcium levels</NAME>
<GROUP_LABEL_1>Low salt</GROUP_LABEL_1>
<GROUP_LABEL_2>Normal salt</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low salt</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours normal salt</GRAPH_LABEL_2>
<CONT_DATA CI_END="-15.17062690435501" CI_START="-74.829373095645" EFFECT_SIZE="-45.0" ESTIMABLE="YES" MEAN_1="271.0" MEAN_2="316.0" MODIFIED="2012-07-06 18:31:24 +1000" MODIFIED_BY="[Empty name]" ORDER="22" SD_1="86.0" SD_2="129.0" SE="15.219347565024295" STUDY_ID="STD-Nouvenne-2010" TOTAL_1="108" TOTAL_2="102" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.02" MODIFIED="2013-08-12 18:22:04 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="102" TOTAL_2="108" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Urinary oxalate levels</NAME>
<GROUP_LABEL_1>Low salt</GROUP_LABEL_1>
<GROUP_LABEL_2>Normal salt</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low salt</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours normal salt</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.5572078642180474" CI_START="-6.442792135781953" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="28.0" MEAN_2="32.0" MODIFIED="2012-07-06 18:32:27 +1000" MODIFIED_BY="[Empty name]" ORDER="23" SD_1="8.0" SD_2="10.0" SE="1.2463454201456685" STUDY_ID="STD-Nouvenne-2010" TOTAL_1="102" TOTAL_2="108" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2014-02-04 13:44:18 +1100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>
<I>Phyllanthus niruri </I>versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.01" MODIFIED="2014-02-04 10:27:26 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="8" TOTAL_2="12" UNITS="mg/kg/d" WEIGHT="0.0" Z="0.0">
<NAME>Urinary calcium levels</NAME>
<GROUP_LABEL_1>
<I>Phyllanthus niuri</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>Phyllanthus niuri</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.17209061321015984" CI_START="-2.37209061321016" EFFECT_SIZE="-1.1" ESTIMABLE="YES" MEAN_1="3.4" MEAN_2="4.5" MODIFIED="2012-07-06 18:37:55 +1000" MODIFIED_BY="[Empty name]" ORDER="28" SD_1="1.1" SD_2="1.8" SE="0.6490377492873585" STUDY_ID="STD-Nishiura-2004" TOTAL_1="8" TOTAL_2="12" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2014-02-04 10:32:23 +1100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Unprocessed wheat bran</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.01" MODIFIED="2014-02-04 10:32:23 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="9" TOTAL_2="8" UNITS="mg/d" WEIGHT="0.0" Z="0.0">
<NAME>Urinary calcium levels</NAME>
<GROUP_LABEL_1>Wheat bran</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours wheat bran</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-30.664101270155456" CI_START="-98.93589872984445" EFFECT_SIZE="-64.79999999999995" ESTIMABLE="YES" MEAN_1="267.1" MEAN_2="331.9" MODIFIED="2012-07-06 18:39:20 +1000" MODIFIED_BY="[Empty name]" ORDER="29" SD_1="37.4" SD_2="34.4" SE="17.416594896183863" STUDY_ID="STD-Gleeson-1990" TOTAL_1="9" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.02" MODIFIED="2014-02-04 10:28:06 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="20.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="9" TOTAL_2="8" UNITS="mg/d" WEIGHT="0.0" Z="0.0">
<NAME>Urinary oxalate levels</NAME>
<GROUP_LABEL_1>Wheat bran</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours wheat bran</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="19.02547057222824" CI_START="8.374529427771751" EFFECT_SIZE="13.699999999999996" ESTIMABLE="YES" MEAN_1="57.3" MEAN_2="43.6" MODIFIED="2012-07-06 18:40:26 +1000" MODIFIED_BY="[Empty name]" ORDER="30" SD_1="5.8" SD_2="5.4" SE="2.7171267504070875" STUDY_ID="STD-Gleeson-1990" TOTAL_1="9" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2014-02-04 13:48:58 +1100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-01-29 09:58:08 +1100" MODIFIED_BY="Ann Jones" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAeIAAAGQCAYAAAByA2NpAAAWX0lEQVR42u3d646rOhKA0X7/l575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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-02-04 13:48:58 +1100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAADnCAMAAAD7EqYIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2014-02-04 13:48:58 +1100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAASQAAAGwCAIAAACPbI/uAAAUCUlEQVR42u3dsY4cxxHG8QUECA4u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=
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2014-02-04 15:07:01 +1100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2012-07-12 01:39:59 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-08-04 16:57:42 +1000" MODIFIED_BY="Narelle S Willis">Electronic search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2012-07-12 01:39:59 +1000" MODIFIED_BY="[Empty name]">
<TABLE COLS="2" ROWS="4">
<TR>
<TH>
<P>Database</P>
</TH>
<TH>
<P>Search terms</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>CENTRAL</P>
</TD>
<TD>
<OL>
<LI>MeSH descriptor Hypercalciuria, this term only</LI>
<LI>MeSH descriptor Calcium Metabolism Disorders, this term only</LI>
<LI>(hypercalciuri*):ti,ab,kw in Clinical Trials</LI>
<LI>(#1 OR #2 OR #3)</LI>
</OL>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>MEDLINE</P>
</TD>
<TD>
<OL>
<LI>Hypercalciuria/</LI>
<LI>hypercalciuri$.tw.</LI>
<LI>Calcium Metabolism Disorders/</LI>
<LI>or/1-3</LI>
</OL>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>EMBASE</P>
</TD>
<TD>
<OL>
<LI>Idiopathic Hypercalciuria/</LI>
<LI>hypercalciuria$.tw.</LI>
<LI>or/1-2</LI>
</OL>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2014-02-04 15:07:01 +1100" MODIFIED_BY="Ann Jones" NO="2">
<TITLE MODIFIED="2013-03-21 15:16:56 +1100" MODIFIED_BY="Ann Jones">Risk of bias assessment tool</TITLE>
<APPENDIX_BODY MODIFIED="2014-02-04 15:07:01 +1100" MODIFIED_BY="Ann Jones">
<TABLE COLS="2" ROWS="22">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Potential source of bias</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Assessment criteria</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Random sequence generation</B>
</P>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>Random number table; computer random number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots; minimization (minimization may be implemented without a random element, and this is considered to be equivalent to being random).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Sequence generated by odd or even date of birth; date (or day) of admission; sequence generated by hospital or clinic record number; allocation by judgement of the clinician; by preference of the participant; based on the results of a laboratory test or a series of tests; by availability of the intervention.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information about the sequence generation process to permit judgement.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Allocation concealment</B>
</P>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>Randomisation method described that would not allow investigator/participant to know or influence intervention group before eligible participant entered in the study (e.g. central allocation, including telephone, web-based, and pharmacy-controlled, randomisation; sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Using an open random allocation schedule (e.g. a list of random numbers); assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or non-opaque or not sequentially numbered); alternation or rotation; date of birth; case record number; any other explicitly unconcealed procedure.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear</I>: Randomisation stated but no information on method used is available.</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3" VALIGN="TOP">
<P>
<B>Blinding of participants and personnel</B>
</P>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</TD>
<TD>
<P>
<I>Low risk of bias</I>:<I> </I>No blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding; blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias</I>: No blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding; blinding of key study participants and personnel attempted, but likely that the blinding could have been broken, and the outcome is likely to be influenced by lack of blinding.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear</I>: Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Blinding of outcome assessment</B>
</P>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors.</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>No blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding; blinding of outcome assessment ensured, and unlikely that the blinding could have been broken.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>No blinding of outcome assessment, and the outcome measurement is likely to be influenced by lack of blinding; blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blinding.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Incomplete outcome data</B>
</P>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data.</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>No missing outcome data; reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias); missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size; missing data have been imputed using appropriate methods.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size; &#8216;as-treated&#8217; analysis done with substantial departure of the intervention received from that assigned at randomisation; potentially inappropriate application of simple imputation.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Selective reporting</B>
</P>
<P>Reporting bias due to selective outcome reporting</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>The study protocol is available and all of the study&#8217;s pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way; the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified (convincing text of this nature may be uncommon).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Not all of the study&#8217;s pre-specified primary outcomes have been reported; one or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not pre-specified; one or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect); one or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis; the study report fails to include results for a key outcome that would be expected to have been reported for such a study.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Other bias</B>
</P>
<P>Bias due to problems not covered elsewhere in the table</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>The study appears to be free of other sources of bias.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias:</I> Had a potential source of bias related to the specific study design used; stopped early due to some data-dependent process (including a formal-stopping rule); had extreme baseline imbalance; has been claimed to have been fraudulent; had some other problem.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to assess whether an important risk of bias exists; insufficient rationale or evidence that an identified problem will introduce bias.</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2010-02-24 19:02:39 +1100" MODIFIED_BY="[Empty name]">
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;Studies included: 5&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;Full text records assessed: 27&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;Abstracts screened: 171&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;Records identified from Specialised Register: 317&lt;/p&gt;">
<OUT TEXT="&lt;p&gt;Records excluded based on title/abstract: 146&lt;/p&gt;"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;Records excluded: 144&lt;/p&gt;&lt;p&gt;(not RCT; wrong population; wrong intervention)&lt;/p&gt;"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;Records excluded: 22 (18 studies): not RCT (4); wrong population/no relevant data (17); wrong intervention (1)&lt;/p&gt;&lt;p&gt;&lt;/p&gt;"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>